grifols sa  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report grifols sa  product pipeline review   published by global markets direct product code  published april   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license grifols sa  product pipeline review   published april   content info  pages description summary global markets directs grifols sa  product pipeline review   provides an overview of the grifols sas pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of grifols sas complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of grifols sa including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of grifols sas human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the grifols sas pipeline products reasons to buy evaluate grifols sas strategic position with total access to detailed information on its product pipeline assess the growth potential of grifols sa in its therapy areas of focus identify new drug targets and therapeutic classes in the grifols sas rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of grifols sa and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of grifols sa develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of grifols sa and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures grifols sa snapshot grifols sa overview key information key facts grifols sa  research and development overview key therapeutic areas grifols sa  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities grifols sa  pipeline products glance grifols sa  late stage pipeline products phase iii productscombination treatment modalities grifols sa  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities phase  productscombination treatment modalities grifols sa  early stage pipeline products preclinical productscombination treatment modalities grifols sa  unknown stage pipeline products unknown productscombination treatment modalities grifols sa  drug profiles albumin human product description mechanism of action rd progress ard product description mechanism of action rd progress immune globulin human product description mechanism of action rd progress recombinant api product description mechanism of action rd progress human plasmin product description mechanism of action rd progress fibrinogen concentrate human product description mechanism of action rd progress ard product description mechanism of action rd progress human coagulation factorviii recombinant product description mechanism of action rd progress recombinant plasmin product description mechanism of action rd progress grifols sa  pipeline analysis grifols sa  pipeline products by target grifols sa  pipeline products by route of administration grifols sa  pipeline products by molecule type grifols sa  pipeline products by mechanism of action grifols sa  recent pipeline updates grifols sa  dormant projects grifols sa  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables grifols sa key information grifols sa key facts grifols sa  pipeline by indication  grifols sa  pipeline by stage of development  grifols sa  monotherapy products in pipeline  grifols sa  partnered products in pipeline  grifols sa  partnered products combination treatment modalities  grifols sa  phase iii  grifols sa  phase ii  grifols sa  phase i  grifols sa  phase   grifols sa  preclinical  grifols sa  unknown  grifols sa  pipeline by target  grifols sa  pipeline by route of administration  grifols sa  pipeline by molecule type  grifols sa  pipeline products by mechanism of action  grifols sa  recent pipeline updates  grifols sa  dormant developmental projects grifols sa other locations grifols sa subsidiaries list of figures grifols sa  pipeline by top  indication  grifols sa  pipeline by stage of development  grifols sa  monotherapy products in pipeline  grifols sa  pipeline by top  target  grifols sa  pipeline by top  route of administration  grifols sa  pipeline by top  molecule type  grifols sa  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved security check required facebookjoin or log into facebook   email or phonepasswordforgot accountlog indo you want to join facebooksign upsign upsecurity checkplease enter the text belowcant read the text abovetry another text or an audio captchatext in the boxwhats thissecurity checkthis is a standard security test that we use to prevent spammers from creating fake accounts and spamming userssubmitenglish usespañolfrançais franceالعربيةportuguês brasilitaliano한국어deutschहिन्दीmessengerfacebook litepeopleplacesgameslocationscelebritiesmarketplacegroupsrecipesmomentsinstagramaboutcreate adcreate pagedeveloperscareersprivacycookiesad choicestermssettingsactivity log facebook   grifols  wikipedia grifols from wikipedia the free encyclopedia jump to navigation search grifols sa type sociedad anónima traded as bmad grf nasdaq grfs industry pharmaceuticals chemicals founded  headquarters barcelona catalonia spain key people víctor grifols chairman and ceo products plasma derivatives in vitro diagnostic products nonbiological products for laboratories and hospitals revenue € million  € million   operating income € million  € million   profit € million  € million  total assets € million  € million  total equity € million  € million  number of employees   average   average website wwwgrifolscom grifols sa catalan ɡɾiˈfɔɫs is a european multinational pharmaceutical and chemical company from catalonia principally a producer of blood plasmabased products a field in which it is the european leader and largest worldwide the company also supplies devices instruments and reagents for clinical testing laboratories contents  main products  main operations  ownership  history  references  further reading  external links main productsedit grifols is the major world supplier of ivig albumin factor viii and other plasmaderived products main operationsedit in  the company had  million litres per year of blood fractionation capacity from three plants one at parets del vallès near barcelona in spain  million litres per year another in los angeles  million litres but being expanded to  million litres and a site in clayton nc in the united states the company owns  plasmapheresis centres where it collects around  million litres of plasma per year ownershipedit grifols was listed on the madrid stock exchange in may  the stock became part of the ibex  index in january  historyedit human immunoglobulin for antitetanus use and antithrombin produced by grifols grifols origin lies in the laboratory founded in  in barcelona by dr josé a grifols roig a hematologist and scientist dr grifols was the first researcher to publish the plasmapheresis procedure in  the company introduced its liquid ivig product into the european market in the mids probitas pharma sa was incorporated with high limited liability under spanish law on  june  on  june  the company changed its name to grifols sa in  the company acquired certain assets of the los angelesbased alpha therapeutic us subsidiary of mitsubishi pharma as the basis of its american expansion on may   grifols securities were listed on spain’s mercado continuo in  csl limited attempted to takeover talecris biotherapeutics the former plasma business of bayer healthcare llc biological products division for  billion but was stopped by the federal trade commission on june   a year after announcing the  billion deal grifols completed a takeover of talecris biotherapeutics headquartered in research triangle park in north carolina with over  employees grifols acquired the blood transfusion diagnostics unit from novartis in  as a platform for global expansion this unit is based in emeryville california and was a part of chiron acquired by novartis in  in  the company acquired a  stake in alkahest as part of planned codevelopment of plasmabased products for the treatment of cognitive decline in aging and disorders of the cns including alzheimers in december  grifols acquired hologics interest in their existing joint blood screening unit for  billion referencesedit  a b c d e f group annual consolidated accounts auditors report and directors report for the financial year  grifols retrieved  selfpublished source  smyth sharon gore gareth  june  santander sabadell sol melia urbas iberia preview bloomberg archived from the original on  october  retrieved    a b c staff december  novartis sells blood transfusion dx unit to grifols genetic engineering  biotechnology news paper   p    dowsett sonya  january  blood firm grifols sees  sales up  pct reuters retrieved    grifols sa formerly probitas pharma sa and subsidiaries consolidated annual accounts prepared in accordance with international financial reporting standards as adopted for use in the european union and consolidated directors report  december  retrieved  selfpublished source  mitsubishi pharma to withdraw from us plasma fractionation business as us subsidiary transfers operations press release mitsubishi pharma corporation  april  retrieved    staff  may  news in brief third time lucky for grifols financial news london retrieved    announcing the launch of talecris biotherapeutics press release talecris  april  retrieved  – via businesswire   ftc authorizes suit to stop csls proposed  billion acquisition of talecris biotherapeutics  retrieved    wolf alan m  spanish buyer set to take over talecris news  observer retrieved    staff  april  grifols makes m investment in alkahest news industry watch genetic engineering  biotechnology news paper      httpwwwgenengnewscomgennewshighlightsgrifolsbuyshologicsshareinbloodscreeningunitforb further readingedit httpopenaccessuoceduwebappsobitstreamgrifolsfactorescompetitividadalargoplazopdf external linksedit wikimedia commons has media related to grifols companies portal official website v t e ibex  companies of spain abengoa abertis acs amadeus it group arcelormittal banco bilbao vizcaya argentaria banco popular español banco sabadell banco santander bankia bankinter bolsas y mercados españoles caixabank dia enagás ferrovial fomento de construcciones y contratas gamesa corporación tecnológica gas natural grifols iberdrola inditex indra sistemas international airlines group jazztel mapfre mediaset españa comunicación obrascón huarte lain red eléctrica de españa repsol sacyr vallehermoso técnicas reunidas telefónica viscofan retrieved from httpsenwikipediaorgwindexphptitlegrifolsoldid categories companies listed on nasdaqpharmaceutical companies of spaincompanies established in companies based in barcelonaibex establishments in spaincompanies listed on the madrid stock exchangespanish brandshidden categories accuracy disputes from june pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages catalàdeutschespañolفارسیfrançais edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view grifols  wikipedia grifols from wikipedia the free encyclopedia jump to navigation search grifols sa type sociedad anónima traded as bmad grf nasdaq grfs industry pharmaceuticals chemicals founded  headquarters barcelona catalonia spain key people víctor grifols chairman and ceo products plasma derivatives in vitro diagnostic products nonbiological products for laboratories and hospitals revenue € million  € million   operating income € million  € million   profit € million  € million  total assets € million  € million  total equity € million  € million  number of employees   average   average website wwwgrifolscom grifols sa catalan ɡɾiˈfɔɫs is a european multinational pharmaceutical and chemical company from catalonia principally a producer of blood plasmabased products a field in which it is the european leader and largest worldwide the company also supplies devices instruments and reagents for clinical testing laboratories contents  main products  main operations  ownership  history  references  further reading  external links main productsedit grifols is the major world supplier of ivig albumin factor viii and other plasmaderived products main operationsedit in  the company had  million litres per year of blood fractionation capacity from three plants one at parets del vallès near barcelona in spain  million litres per year another in los angeles  million litres but being expanded to  million litres and a site in clayton nc in the united states the company owns  plasmapheresis centres where it collects around  million litres of plasma per year ownershipedit grifols was listed on the madrid stock exchange in may  the stock became part of the ibex  index in january  historyedit human immunoglobulin for antitetanus use and antithrombin produced by grifols grifols origin lies in the laboratory founded in  in barcelona by dr josé a grifols roig a hematologist and scientist dr grifols was the first researcher to publish the plasmapheresis procedure in  the company introduced its liquid ivig product into the european market in the mids probitas pharma sa was incorporated with high limited liability under spanish law on  june  on  june  the company changed its name to grifols sa in  the company acquired certain assets of the los angelesbased alpha therapeutic us subsidiary of mitsubishi pharma as the basis of its american expansion on may   grifols securities were listed on spain’s mercado continuo in  csl limited attempted to takeover talecris biotherapeutics the former plasma business of bayer healthcare llc biological products division for  billion but was stopped by the federal trade commission on june   a year after announcing the  billion deal grifols completed a takeover of talecris biotherapeutics headquartered in research triangle park in north carolina with over  employees grifols acquired the blood transfusion diagnostics unit from novartis in  as a platform for global expansion this unit is based in emeryville california and was a part of chiron acquired by novartis in  in  the company acquired a  stake in alkahest as part of planned codevelopment of plasmabased products for the treatment of cognitive decline in aging and disorders of the cns including alzheimers in december  grifols acquired hologics interest in their existing joint blood screening unit for  billion referencesedit  a b c d e f group annual consolidated accounts auditors report and directors report for the financial year  grifols retrieved  selfpublished source  smyth sharon gore gareth  june  santander sabadell sol melia urbas iberia preview bloomberg archived from the original on  october  retrieved    a b c staff december  novartis sells blood transfusion dx unit to grifols genetic engineering  biotechnology news paper   p    dowsett sonya  january  blood firm grifols sees  sales up  pct reuters retrieved    grifols sa formerly probitas pharma sa and subsidiaries consolidated annual accounts prepared in accordance with international financial reporting standards as adopted for use in the european union and consolidated directors report  december  retrieved  selfpublished source  mitsubishi pharma to withdraw from us plasma fractionation business as us subsidiary transfers operations press release mitsubishi pharma corporation  april  retrieved    staff  may  news in brief third time lucky for grifols financial news london retrieved    announcing the launch of talecris biotherapeutics press release talecris  april  retrieved  – via businesswire   ftc authorizes suit to stop csls proposed  billion acquisition of talecris biotherapeutics  retrieved    wolf alan m  spanish buyer set to take over talecris news  observer retrieved    staff  april  grifols makes m investment in alkahest news industry watch genetic engineering  biotechnology news paper      httpwwwgenengnewscomgennewshighlightsgrifolsbuyshologicsshareinbloodscreeningunitforb further readingedit httpopenaccessuoceduwebappsobitstreamgrifolsfactorescompetitividadalargoplazopdf external linksedit wikimedia commons has media related to grifols companies portal official website v t e ibex  companies of spain abengoa abertis acs amadeus it group arcelormittal banco bilbao vizcaya argentaria banco popular español banco sabadell banco santander bankia bankinter bolsas y mercados españoles caixabank dia enagás ferrovial fomento de construcciones y contratas gamesa corporación tecnológica gas natural grifols iberdrola inditex indra sistemas international airlines group jazztel mapfre mediaset españa comunicación obrascón huarte lain red eléctrica de españa repsol sacyr vallehermoso técnicas reunidas telefónica viscofan retrieved from httpsenwikipediaorgwindexphptitlegrifolsoldid categories companies listed on nasdaqpharmaceutical companies of spaincompanies established in companies based in barcelonaibex establishments in spaincompanies listed on the madrid stock exchangespanish brandshidden categories accuracy disputes from june pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages catalàdeutschespañolفارسیfrançais edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view grifols  wikipedia grifols from wikipedia the free encyclopedia jump to navigation search grifols sa type sociedad anónima traded as bmad grf nasdaq grfs industry pharmaceuticals chemicals founded  headquarters barcelona catalonia spain key people víctor grifols chairman and ceo products plasma derivatives in vitro diagnostic products nonbiological products for laboratories and hospitals revenue € million  € million   operating income € million  € million   profit € million  € million  total assets € million  € million  total equity € million  € million  number of employees   average   average website wwwgrifolscom grifols sa catalan ɡɾiˈfɔɫs is a european multinational pharmaceutical and chemical company from catalonia principally a producer of blood plasmabased products a field in which it is the european leader and largest worldwide the company also supplies devices instruments and reagents for clinical testing laboratories contents  main products  main operations  ownership  history  references  further reading  external links main productsedit grifols is the major world supplier of ivig albumin factor viii and other plasmaderived products main operationsedit in  the company had  million litres per year of blood fractionation capacity from three plants one at parets del vallès near barcelona in spain  million litres per year another in los angeles  million litres but being expanded to  million litres and a site in clayton nc in the united states the company owns  plasmapheresis centres where it collects around  million litres of plasma per year ownershipedit grifols was listed on the madrid stock exchange in may  the stock became part of the ibex  index in january  historyedit human immunoglobulin for antitetanus use and antithrombin produced by grifols grifols origin lies in the laboratory founded in  in barcelona by dr josé a grifols roig a hematologist and scientist dr grifols was the first researcher to publish the plasmapheresis procedure in  the company introduced its liquid ivig product into the european market in the mids probitas pharma sa was incorporated with high limited liability under spanish law on  june  on  june  the company changed its name to grifols sa in  the company acquired certain assets of the los angelesbased alpha therapeutic us subsidiary of mitsubishi pharma as the basis of its american expansion on may   grifols securities were listed on spain’s mercado continuo in  csl limited attempted to takeover talecris biotherapeutics the former plasma business of bayer healthcare llc biological products division for  billion but was stopped by the federal trade commission on june   a year after announcing the  billion deal grifols completed a takeover of talecris biotherapeutics headquartered in research triangle park in north carolina with over  employees grifols acquired the blood transfusion diagnostics unit from novartis in  as a platform for global expansion this unit is based in emeryville california and was a part of chiron acquired by novartis in  in  the company acquired a  stake in alkahest as part of planned codevelopment of plasmabased products for the treatment of cognitive decline in aging and disorders of the cns including alzheimers in december  grifols acquired hologics interest in their existing joint blood screening unit for  billion referencesedit  a b c d e f group annual consolidated accounts auditors report and directors report for the financial year  grifols retrieved  selfpublished source  smyth sharon gore gareth  june  santander sabadell sol melia urbas iberia preview bloomberg archived from the original on  october  retrieved    a b c staff december  novartis sells blood transfusion dx unit to grifols genetic engineering  biotechnology news paper   p    dowsett sonya  january  blood firm grifols sees  sales up  pct reuters retrieved    grifols sa formerly probitas pharma sa and subsidiaries consolidated annual accounts prepared in accordance with international financial reporting standards as adopted for use in the european union and consolidated directors report  december  retrieved  selfpublished source  mitsubishi pharma to withdraw from us plasma fractionation business as us subsidiary transfers operations press release mitsubishi pharma corporation  april  retrieved    staff  may  news in brief third time lucky for grifols financial news london retrieved    announcing the launch of talecris biotherapeutics press release talecris  april  retrieved  – via businesswire   ftc authorizes suit to stop csls proposed  billion acquisition of talecris biotherapeutics  retrieved    wolf alan m  spanish buyer set to take over talecris news  observer retrieved    staff  april  grifols makes m investment in alkahest news industry watch genetic engineering  biotechnology news paper      httpwwwgenengnewscomgennewshighlightsgrifolsbuyshologicsshareinbloodscreeningunitforb further readingedit httpopenaccessuoceduwebappsobitstreamgrifolsfactorescompetitividadalargoplazopdf external linksedit wikimedia commons has media related to grifols companies portal official website v t e ibex  companies of spain abengoa abertis acs amadeus it group arcelormittal banco bilbao vizcaya argentaria banco popular español banco sabadell banco santander bankia bankinter bolsas y mercados españoles caixabank dia enagás ferrovial fomento de construcciones y contratas gamesa corporación tecnológica gas natural grifols iberdrola inditex indra sistemas international airlines group jazztel mapfre mediaset españa comunicación obrascón huarte lain red eléctrica de españa repsol sacyr vallehermoso técnicas reunidas telefónica viscofan retrieved from httpsenwikipediaorgwindexphptitlegrifolsoldid categories companies listed on nasdaqpharmaceutical companies of spaincompanies established in companies based in barcelonaibex establishments in spaincompanies listed on the madrid stock exchangespanish brandshidden categories accuracy disputes from june pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages catalàdeutschespañolفارسیfrançais edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view grifols  wikipedia grifols from wikipedia the free encyclopedia jump to navigation search grifols sa type sociedad anónima traded as bmad grf nasdaq grfs industry pharmaceuticals chemicals founded  headquarters barcelona catalonia spain key people víctor grifols chairman and ceo products plasma derivatives in vitro diagnostic products nonbiological products for laboratories and hospitals revenue € million  € million   operating income € million  € million   profit € million  € million  total assets € million  € million  total equity € million  € million  number of employees   average   average website wwwgrifolscom grifols sa catalan ɡɾiˈfɔɫs is a european multinational pharmaceutical and chemical company from catalonia principally a producer of blood plasmabased products a field in which it is the european leader and largest worldwide the company also supplies devices instruments and reagents for clinical testing laboratories contents  main products  main operations  ownership  history  references  further reading  external links main productsedit grifols is the major world supplier of ivig albumin factor viii and other plasmaderived products main operationsedit in  the company had  million litres per year of blood fractionation capacity from three plants one at parets del vallès near barcelona in spain  million litres per year another in los angeles  million litres but being expanded to  million litres and a site in clayton nc in the united states the company owns  plasmapheresis centres where it collects around  million litres of plasma per year ownershipedit grifols was listed on the madrid stock exchange in may  the stock became part of the ibex  index in january  historyedit human immunoglobulin for antitetanus use and antithrombin produced by grifols grifols origin lies in the laboratory founded in  in barcelona by dr josé a grifols roig a hematologist and scientist dr grifols was the first researcher to publish the plasmapheresis procedure in  the company introduced its liquid ivig product into the european market in the mids probitas pharma sa was incorporated with high limited liability under spanish law on  june  on  june  the company changed its name to grifols sa in  the company acquired certain assets of the los angelesbased alpha therapeutic us subsidiary of mitsubishi pharma as the basis of its american expansion on may   grifols securities were listed on spain’s mercado continuo in  csl limited attempted to takeover talecris biotherapeutics the former plasma business of bayer healthcare llc biological products division for  billion but was stopped by the federal trade commission on june   a year after announcing the  billion deal grifols completed a takeover of talecris biotherapeutics headquartered in research triangle park in north carolina with over  employees grifols acquired the blood transfusion diagnostics unit from novartis in  as a platform for global expansion this unit is based in emeryville california and was a part of chiron acquired by novartis in  in  the company acquired a  stake in alkahest as part of planned codevelopment of plasmabased products for the treatment of cognitive decline in aging and disorders of the cns including alzheimers in december  grifols acquired hologics interest in their existing joint blood screening unit for  billion referencesedit  a b c d e f group annual consolidated accounts auditors report and directors report for the financial year  grifols retrieved  selfpublished source  smyth sharon gore gareth  june  santander sabadell sol melia urbas iberia preview bloomberg archived from the original on  october  retrieved    a b c staff december  novartis sells blood transfusion dx unit to grifols genetic engineering  biotechnology news paper   p    dowsett sonya  january  blood firm grifols sees  sales up  pct reuters retrieved    grifols sa formerly probitas pharma sa and subsidiaries consolidated annual accounts prepared in accordance with international financial reporting standards as adopted for use in the european union and consolidated directors report  december  retrieved  selfpublished source  mitsubishi pharma to withdraw from us plasma fractionation business as us subsidiary transfers operations press release mitsubishi pharma corporation  april  retrieved    staff  may  news in brief third time lucky for grifols financial news london retrieved    announcing the launch of talecris biotherapeutics press release talecris  april  retrieved  – via businesswire   ftc authorizes suit to stop csls proposed  billion acquisition of talecris biotherapeutics  retrieved    wolf alan m  spanish buyer set to take over talecris news  observer retrieved    staff  april  grifols makes m investment in alkahest news industry watch genetic engineering  biotechnology news paper      httpwwwgenengnewscomgennewshighlightsgrifolsbuyshologicsshareinbloodscreeningunitforb further readingedit httpopenaccessuoceduwebappsobitstreamgrifolsfactorescompetitividadalargoplazopdf external linksedit wikimedia commons has media related to grifols companies portal official website v t e ibex  companies of spain abengoa abertis acs amadeus it group arcelormittal banco bilbao vizcaya argentaria banco popular español banco sabadell banco santander bankia bankinter bolsas y mercados españoles caixabank dia enagás ferrovial fomento de construcciones y contratas gamesa corporación tecnológica gas natural grifols iberdrola inditex indra sistemas international airlines group jazztel mapfre mediaset españa comunicación obrascón huarte lain red eléctrica de españa repsol sacyr vallehermoso técnicas reunidas telefónica viscofan retrieved from httpsenwikipediaorgwindexphptitlegrifolsoldid categories companies listed on nasdaqpharmaceutical companies of spaincompanies established in companies based in barcelonaibex establishments in spaincompanies listed on the madrid stock exchangespanish brandshidden categories accuracy disputes from june pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages catalàdeutschespañolفارسیfrançais edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view grifols  wikipedia grifols from wikipedia the free encyclopedia jump to navigation search grifols sa type sociedad anónima traded as bmad grf nasdaq grfs industry pharmaceuticals chemicals founded  headquarters barcelona catalonia spain key people víctor grifols chairman and ceo products plasma derivatives in vitro diagnostic products nonbiological products for laboratories and hospitals revenue € million  € million   operating income € million  € million   profit € million  € million  total assets € million  € million  total equity € million  € million  number of employees   average   average website wwwgrifolscom grifols sa catalan ɡɾiˈfɔɫs is a european multinational pharmaceutical and chemical company from catalonia principally a producer of blood plasmabased products a field in which it is the european leader and largest worldwide the company also supplies devices instruments and reagents for clinical testing laboratories contents  main products  main operations  ownership  history  references  further reading  external links main productsedit grifols is the major world supplier of ivig albumin factor viii and other plasmaderived products main operationsedit in  the company had  million litres per year of blood fractionation capacity from three plants one at parets del vallès near barcelona in spain  million litres per year another in los angeles  million litres but being expanded to  million litres and a site in clayton nc in the united states the company owns  plasmapheresis centres where it collects around  million litres of plasma per year ownershipedit grifols was listed on the madrid stock exchange in may  the stock became part of the ibex  index in january  historyedit human immunoglobulin for antitetanus use and antithrombin produced by grifols grifols origin lies in the laboratory founded in  in barcelona by dr josé a grifols roig a hematologist and scientist dr grifols was the first researcher to publish the plasmapheresis procedure in  the company introduced its liquid ivig product into the european market in the mids probitas pharma sa was incorporated with high limited liability under spanish law on  june  on  june  the company changed its name to grifols sa in  the company acquired certain assets of the los angelesbased alpha therapeutic us subsidiary of mitsubishi pharma as the basis of its american expansion on may   grifols securities were listed on spain’s mercado continuo in  csl limited attempted to takeover talecris biotherapeutics the former plasma business of bayer healthcare llc biological products division for  billion but was stopped by the federal trade commission on june   a year after announcing the  billion deal grifols completed a takeover of talecris biotherapeutics headquartered in research triangle park in north carolina with over  employees grifols acquired the blood transfusion diagnostics unit from novartis in  as a platform for global expansion this unit is based in emeryville california and was a part of chiron acquired by novartis in  in  the company acquired a  stake in alkahest as part of planned codevelopment of plasmabased products for the treatment of cognitive decline in aging and disorders of the cns including alzheimers in december  grifols acquired hologics interest in their existing joint blood screening unit for  billion referencesedit  a b c d e f group annual consolidated accounts auditors report and directors report for the financial year  grifols retrieved  selfpublished source  smyth sharon gore gareth  june  santander sabadell sol melia urbas iberia preview bloomberg archived from the original on  october  retrieved    a b c staff december  novartis sells blood transfusion dx unit to grifols genetic engineering  biotechnology news paper   p    dowsett sonya  january  blood firm grifols sees  sales up  pct reuters retrieved    grifols sa formerly probitas pharma sa and subsidiaries consolidated annual accounts prepared in accordance with international financial reporting standards as adopted for use in the european union and consolidated directors report  december  retrieved  selfpublished source  mitsubishi pharma to withdraw from us plasma fractionation business as us subsidiary transfers operations press release mitsubishi pharma corporation  april  retrieved    staff  may  news in brief third time lucky for grifols financial news london retrieved    announcing the launch of talecris biotherapeutics press release talecris  april  retrieved  – via businesswire   ftc authorizes suit to stop csls proposed  billion acquisition of talecris biotherapeutics  retrieved    wolf alan m  spanish buyer set to take over talecris news  observer retrieved    staff  april  grifols makes m investment in alkahest news industry watch genetic engineering  biotechnology news paper      httpwwwgenengnewscomgennewshighlightsgrifolsbuyshologicsshareinbloodscreeningunitforb further readingedit httpopenaccessuoceduwebappsobitstreamgrifolsfactorescompetitividadalargoplazopdf external linksedit wikimedia commons has media related to grifols companies portal official website v t e ibex  companies of spain abengoa abertis acs amadeus it group arcelormittal banco bilbao vizcaya argentaria banco popular español banco sabadell banco santander bankia bankinter bolsas y mercados españoles caixabank dia enagás ferrovial fomento de construcciones y contratas gamesa corporación tecnológica gas natural grifols iberdrola inditex indra sistemas international airlines group jazztel mapfre mediaset españa comunicación obrascón huarte lain red eléctrica de españa repsol sacyr vallehermoso técnicas reunidas telefónica viscofan retrieved from httpsenwikipediaorgwindexphptitlegrifolsoldid categories companies listed on nasdaqpharmaceutical companies of spaincompanies established in companies based in barcelonaibex establishments in spaincompanies listed on the madrid stock exchangespanish brandshidden categories accuracy disputes from june pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages catalàdeutschespañolفارسیfrançais edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view grifols sa  product pipeline review   infomarketreportscentercom  us x login sign up facebook twitter linkedin google  mrc blog youtube grifols sa  product pipeline review   home  pharmaceuticals  global markets direct  grifols sa  product pipeline review   report details grifols sa  product pipeline review   sku gmdapr category pharmaceuticals publisher global markets direct pages  published apr skugmdapr categorypharmaceuticals publisherglobal markets direct pages published onapr request discount pay by wireinvoice description table of content list of figures request sample description grifols sa  product pipeline review   summary global markets directs grifols sa  product pipeline review   provides an overview of the grifols sas pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of grifols sas complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of grifols sa including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of grifols sas human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the grifols sas pipeline products reasons to buy  evaluate grifols sas strategic position with total access to detailed information on its product pipeline  assess the growth potential of grifols sa in its therapy areas of focus  identify new drug targets and therapeutic classes in the grifols sas rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of grifols sa and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of grifols sa  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of grifols sa and identify potential opportunities in those areas  avoid intellectual property rights related issues newspress release precision medicine how the life science industry can improve outcomes through to achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option researchers in drug rd need to better understand and manage the reams of unstructured datread more regenerative medicine market to hit  billion by  the current regenerative medicine market is worth  billion globally and will hit over  billion by  as impact of trump administrationread more  benefits of microneedlingmicroneedling hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your faceread more table of content table of contents table of contents  list of tables  list of figures  grifols sa snapshot  grifols sa overview  key information  key facts  grifols sa  research and development overview  key therapeutic areas  grifols sa  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  grifols sa  pipeline products glance  grifols sa  late stage pipeline products  phase iii productscombination treatment modalities  grifols sa  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  phase  productscombination treatment modalities  grifols sa  early stage pipeline products  preclinical productscombination treatment modalities  grifols sa  unknown stage pipeline products  unknown productscombination treatment modalities  grifols sa  drug profiles  albumin human  product description  mechanism of action  rd progress  ard  product description  mechanism of action  rd progress  immune globulin human  product description  mechanism of action  rd progress  recombinant api  product description  mechanism of action  rd progress  human plasmin  product description  mechanism of action  rd progress  fibrinogen concentrate human  product description  mechanism of action  rd progress  ard  product description  mechanism of action  rd progress  human coagulation factorviii recombinant  product description  mechanism of action  rd progress  recombinant plasmin  product description  mechanism of action  rd progress  grifols sa  pipeline analysis  grifols sa  pipeline products by target  grifols sa  pipeline products by route of administration  grifols sa  pipeline products by molecule type  grifols sa  pipeline products by mechanism of action  grifols sa  recent pipeline updates  grifols sa  dormant projects  grifols sa  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of figures list of tables grifols sa key information  grifols sa key facts  grifols sa  pipeline by indication   grifols sa  pipeline by stage of development   grifols sa  monotherapy products in pipeline   grifols sa  partnered products in pipeline   grifols sa  partnered products combination treatment modalities   grifols sa  phase iii   grifols sa  phase ii   grifols sa  phase i   grifols sa  phase    grifols sa  preclinical   grifols sa  unknown   grifols sa  pipeline by target   grifols sa  pipeline by route of administration   grifols sa  pipeline by molecule type   grifols sa  pipeline products by mechanism of action   grifols sa  recent pipeline updates   grifols sa  dormant developmental projects  grifols sa other locations  grifols sa subsidiaries  list of figures grifols sa  pipeline by top  indication   grifols sa  pipeline by stage of development   grifols sa  monotherapy products in pipeline   grifols sa  pipeline by top  target   grifols sa  pipeline by top  route of administration   grifols sa  pipeline by top  molecule type   grifols sa  pipeline products by top  mechanism of action   please select license type single user electronic pdf   site user electronic pdf   enterprise wide electronic pdf   add to cart buy now related reports global fiberglass electronic products market professional survey report  global fiberglass electrical products market professional survey report  global dispersants for inks market professional survey report  global biochip products market professional survey report  global aluminum flatrolled product market professional survey report  request sample mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send request discount mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send pay by wireinvoice mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  single user electronic pdf site user electronic pdf enterprise wide electronic pdf cd rom hard copy send request quote mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send market reports center  copyright  all rights reserved grifols sa  product pipeline review    reportsnreports market research report welcome guest    registerlogin   contact us   about us      advanced search home ›  pharmaceuticals ›  report detail grifols sa  product pipeline review   published april  no of pages  price  single user license us   corporate user license us     report description table of contents inquire before buying global markets directs grifols sa product pipeline review  provides an overview of the grifols sas pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of grifols sas complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of grifols sa including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of grifols sas human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the grifols sas pipeline productsreasons to buyevaluate grifols sas strategic position with total access to detailed information on its product pipelineassess the growth potential of grifols sa in its therapy areas of focusidentify new drug targets and therapeutic classes in the grifols sas rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of grifols sa and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of grifols sadevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of grifols sa and identify potential opportunities in those areasavoid intellectual property rights related issues grifols sa  product pipeline review   table of contentstable of contents list of tables list of figures grifols sa snapshot grifols sa overview key information key facts grifols sa  research and development overview key therapeutic areas grifols sa  pipeline review pipeline products by stage of development pipeline products  monotherapy grifols sa  pipeline products glance grifols sa  late stage pipeline products phase iii productscombination treatment modalities grifols sa  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities grifols sa  early stage pipeline products preclinical productscombination treatment modalities grifols sa  drug profiles ard product description mechanism of action rd progress immune globulin human product description mechanism of action rd progress albumin human product description mechanism of action rd progress human plasmin product description mechanism of action rd progress recombinant api product description mechanism of action rd progress ard product description mechanism of action rd progress fibrinogen product description mechanism of action rd progress human coagulation factorviii product description mechanism of action rd progress recombinant plasmin product description mechanism of action rd progress grifols sa  pipeline analysis grifols sa  pipeline products by target grifols sa  pipeline products by route of administration grifols sa  pipeline products by molecule type grifols sa  pipeline products by mechanism of action grifols sa  recent pipeline updates grifols sa  dormant projects grifols sa  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesgrifols sa key information grifols sa key facts grifols sa  pipeline by indication  grifols sa  pipeline by stage of development  grifols sa  monotherapy products in pipeline  grifols sa  phase iii  grifols sa  phase ii  grifols sa  phase i  grifols sa  preclinical  grifols sa  pipeline by target  grifols sa  pipeline by route of administration  grifols sa  pipeline by molecule type  grifols sa  pipeline products by mechanism of action  grifols sa  recent pipeline updates  grifols sa  dormant developmental projects grifols sa other locations grifols sa subsidiaries list of figuresgrifols sa  pipeline by top  indication  grifols sa  pipeline by stage of development  grifols sa  monotherapy products in pipeline  grifols sa  pipeline by top  target  grifols sa  pipeline by top  route of administration  grifols sa  pipeline by top  molecule type  grifols sa  pipeline products by top  mechanism of action   published by global markets direct product code global markets direct did you find what you arewere looking for  if not read below and browse through other relevant pages for similar market research reports or get in touch with us through the formcontact info in your right navigation panel and well share relevant market report titles for you to explore related reports  global and japan hypolipidemic drugs market analysis report the global hypolipidemic drugs market is valued at xx million usd in  and is expected to reach xx million usd by the end of  growing at a cagr of xx between  and  japan plays an important role in global market with market size global and europe bacillus subtilis market  analysis and outlook to  this report presents a comprehensive overview of the bacillus subtilis market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynam global and europe antipsychotic drugs market  analysis and outlook to  this report presents a comprehensive overview of the antipsychotic drugs market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynam asiapacific vitamin  mineral supplement market by manufacturers regions type and application forecast to  watersoluble vitamins these vitamins pass in and out of the body easily most do not build up in the bodys cells watersoluble vitamins include vitamin c and the b vitamins thiamine riboflavin niacin pantothenic acid b biotin folic acid asiapacific pressure ulcer treatment products market by manufacturers regions type and application forecast to  pressure ulcer is an open wound on the skin pressure ulcer occurs due to the breakdown of skin and underlying tissues through excessive pressure on an area of the skin some of the symptoms of pressure ulcer are redness of the skin that worsens with asiapacific narcolepsy drug market by manufacturers regions type and application forecast to  narcolepsy is a longterm neurological disorder that involves a decreased ability to regulate sleepwake cycles symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time about  o asiapacific maca extract market by manufacturers regions type and application forecast to  the root vegetable known as maca originates from the peruvian andes maca also known as peruvian ginseng is reported to have numerous health benefits in fact powdered maca is considered a unique superfood that boosts energy improves stamina and e asiapacific lipoic acid market by manufacturers regions type and application forecast to  lipoic acid is a vitaminlike compound found in a slightly yellow crystalline powder form it can be synthetically produced in laboratories for medical use but is found naturally in abundance in foods such as yeast liver kidney broccoli spinach global antipsychotic drugs detailed analysis report  this report splits antipsychotic drugs by product antipsychotic drugs product antidepressant antianxiety drugs this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume  global sodium hyaluronate market professional survey report  this report studies sodium hyaluronate in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to   why reportsnreportscom  market research reports and growing top fortune  organizations trust us for research data  support on call as well as emails your details are safe with us free support for your research requirements report delivery email delivery time upto  hrs  working days upto  hrs max  weekends and public holidays research support  custom research if this business study does not have the data and information analysis you need contact us with your research requirements we explore available market research reports to map your needs and share report titles with you alternatively we can also offer custom research that suits your budget and timelines share your information requirements here connect with us email salesreportsandreportscom call       home category publisher country latest reports markets discounted reports upcoming reports contact us subscription option using our subscription option you get access to market research reports and industry data of consumer goods market as per your needs get the best of consumer goods research reports by utilizing your research budgets in an optimum way more about our subscription option report alerts get email alerts about market research reports from industries and publishers of your interest please enter a valid email id thank you you have successfully subscribed to our report alerts avail upto  discount on below publisher reports technavio azoth analytics   reportsnreports all rights reserved disclamer privacy policy  terms and conditions  our market research blog  sitemap feeds rss  latest reports grifols sa  product pipeline review    acute market reports about us contact us sitemap home our services market research reports business consulting prolonge business leverages plan your own research industry reports country reports press release login register home  healthcare  grifols sa  product pipeline review   grifols sa  product pipeline review   published apr   no of pages   published by global markets direct report summary     table of content     list of tables     list of figures     request sample grifols sa  product pipeline review   summary global markets directs grifols sa  product pipeline review   provides an overview of the grifols sas pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of grifols sas complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of grifols sa including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of grifols sas human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the grifols sas pipeline products reasons to buy  evaluate grifols sas strategic position with total access to detailed information on its product pipeline  assess the growth potential of grifols sa in its therapy areas of focus  identify new drug targets and therapeutic classes in the grifols sas rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of grifols sa and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of grifols sa  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of grifols sa and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  grifols sa snapshot  grifols sa overview  key information  key facts  grifols sa  research and development overview  key therapeutic areas  grifols sa  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  grifols sa  pipeline products glance  grifols sa  late stage pipeline products  phase iii productscombination treatment modalities  grifols sa  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  phase  productscombination treatment modalities  grifols sa  early stage pipeline products  preclinical productscombination treatment modalities  grifols sa  unknown stage pipeline products  unknown productscombination treatment modalities  grifols sa  drug profiles  albumin human  product description  mechanism of action  rd progress  ard  product description  mechanism of action  rd progress  immune globulin human  product description  mechanism of action  rd progress  recombinant api  product description  mechanism of action  rd progress  human plasmin  product description  mechanism of action  rd progress  fibrinogen concentrate human  product description  mechanism of action  rd progress  ard  product description  mechanism of action  rd progress  human coagulation factorviii recombinant  product description  mechanism of action  rd progress  recombinant plasmin  product description  mechanism of action  rd progress  grifols sa  pipeline analysis  grifols sa  pipeline products by target  grifols sa  pipeline products by route of administration  grifols sa  pipeline products by molecule type  grifols sa  pipeline products by mechanism of action  grifols sa  recent pipeline updates  grifols sa  dormant projects  grifols sa  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  grifols sa key information  grifols sa key facts  grifols sa  pipeline by indication   grifols sa  pipeline by stage of development   grifols sa  monotherapy products in pipeline   grifols sa  partnered products in pipeline   grifols sa  partnered products combination treatment modalities   grifols sa  phase iii   grifols sa  phase ii   grifols sa  phase i   grifols sa  phase    grifols sa  preclinical   grifols sa  unknown   grifols sa  pipeline by target   grifols sa  pipeline by route of administration   grifols sa  pipeline by molecule type   grifols sa  pipeline products by mechanism of action   grifols sa  recent pipeline updates   grifols sa  dormant developmental projects  grifols sa other locations  grifols sa subsidiaries  grifols sa  pipeline by top  indication   grifols sa  pipeline by stage of development   grifols sa  monotherapy products in pipeline   grifols sa  pipeline by top  target   grifols sa  pipeline by top  route of administration   grifols sa  pipeline by top  molecule type   grifols sa  pipeline products by top  mechanism of action   choose license type single user   multi user   enterprise   buy now   contact information  research support phone  salesacutemarketreportscom get in touch with us join us on facebook follow us on twitter follow us on linkedin add us on google  home about us customer faq how to order privacy policy terms of use  copyright  acute market reports and its affiliates all rights reserved newsletter sign up signup for latest updates  promos send payment options contact us acute market reports office no  st floor  aditi mall baner pune mh  india toll freeuscanada  india   salesacutemarketreportscom grifols  wikipedia grifols from wikipedia the free encyclopedia jump to navigation search grifols sa type sociedad anónima traded as bmad grf nasdaq grfs industry pharmaceuticals chemicals founded  headquarters barcelona catalonia spain key people víctor grifols chairman and ceo products plasma derivatives in vitro diagnostic products nonbiological products for laboratories and hospitals revenue € million  € million   operating income € million  € million   profit € million  € million  total assets € million  € million  total equity € million  € million  number of employees   average   average website wwwgrifolscom grifols sa catalan ɡɾiˈfɔɫs is a european multinational pharmaceutical and chemical company from catalonia principally a producer of blood plasmabased products a field in which it is the european leader and largest worldwide the company also supplies devices instruments and reagents for clinical testing laboratories contents  main products  main operations  ownership  history  references  further reading  external links main productsedit grifols is the major world supplier of ivig albumin factor viii and other plasmaderived products main operationsedit in  the company had  million litres per year of blood fractionation capacity from three plants one at parets del vallès near barcelona in spain  million litres per year another in los angeles  million litres but being expanded to  million litres and a site in clayton nc in the united states the company owns  plasmapheresis centres where it collects around  million litres of plasma per year ownershipedit grifols was listed on the madrid stock exchange in may  the stock became part of the ibex  index in january  historyedit human immunoglobulin for antitetanus use and antithrombin produced by grifols grifols origin lies in the laboratory founded in  in barcelona by dr josé a grifols roig a hematologist and scientist dr grifols was the first researcher to publish the plasmapheresis procedure in  the company introduced its liquid ivig product into the european market in the mids probitas pharma sa was incorporated with high limited liability under spanish law on  june  on  june  the company changed its name to grifols sa in  the company acquired certain assets of the los angelesbased alpha therapeutic us subsidiary of mitsubishi pharma as the basis of its american expansion on may   grifols securities were listed on spain’s mercado continuo in  csl limited attempted to takeover talecris biotherapeutics the former plasma business of bayer healthcare llc biological products division for  billion but was stopped by the federal trade commission on june   a year after announcing the  billion deal grifols completed a takeover of talecris biotherapeutics headquartered in research triangle park in north carolina with over  employees grifols acquired the blood transfusion diagnostics unit from novartis in  as a platform for global expansion this unit is based in emeryville california and was a part of chiron acquired by novartis in  in  the company acquired a  stake in alkahest as part of planned codevelopment of plasmabased products for the treatment of cognitive decline in aging and disorders of the cns including alzheimers in december  grifols acquired hologics interest in their existing joint blood screening unit for  billion referencesedit  a b c d e f group annual consolidated accounts auditors report and directors report for the financial year  grifols retrieved  selfpublished source  smyth sharon gore gareth  june  santander sabadell sol melia urbas iberia preview bloomberg archived from the original on  october  retrieved    a b c staff december  novartis sells blood transfusion dx unit to grifols genetic engineering  biotechnology news paper   p    dowsett sonya  january  blood firm grifols sees  sales up  pct reuters retrieved    grifols sa formerly probitas pharma sa and subsidiaries consolidated annual accounts prepared in accordance with international financial reporting standards as adopted for use in the european union and consolidated directors report  december  retrieved  selfpublished source  mitsubishi pharma to withdraw from us plasma fractionation business as us subsidiary transfers operations press release mitsubishi pharma corporation  april  retrieved    staff  may  news in brief third time lucky for grifols financial news london retrieved    announcing the launch of talecris biotherapeutics press release talecris  april  retrieved  – via businesswire   ftc authorizes suit to stop csls proposed  billion acquisition of talecris biotherapeutics  retrieved    wolf alan m  spanish buyer set to take over talecris news  observer retrieved    staff  april  grifols makes m investment in alkahest news industry watch genetic engineering  biotechnology news paper      httpwwwgenengnewscomgennewshighlightsgrifolsbuyshologicsshareinbloodscreeningunitforb further readingedit httpopenaccessuoceduwebappsobitstreamgrifolsfactorescompetitividadalargoplazopdf external linksedit wikimedia commons has media related to grifols companies portal official website v t e ibex  companies of spain abengoa abertis acs amadeus it group arcelormittal banco bilbao vizcaya argentaria banco popular español banco sabadell banco santander bankia bankinter bolsas y mercados españoles caixabank dia enagás ferrovial fomento de construcciones y contratas gamesa corporación tecnológica gas natural grifols iberdrola inditex indra sistemas international airlines group jazztel mapfre mediaset españa comunicación obrascón huarte lain red eléctrica de españa repsol sacyr vallehermoso técnicas reunidas telefónica viscofan retrieved from httpsenwikipediaorgwindexphptitlegrifolsoldid categories companies listed on nasdaqpharmaceutical companies of spaincompanies established in companies based in barcelonaibex establishments in spaincompanies listed on the madrid stock exchangespanish brandshidden categories accuracy disputes from june pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages catalàdeutschespañolفارسیfrançais edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view grifols  wikipedia grifols from wikipedia the free encyclopedia jump to navigation search grifols sa type sociedad anónima traded as bmad grf nasdaq grfs industry pharmaceuticals chemicals founded  headquarters barcelona catalonia spain key people víctor grifols chairman and ceo products plasma derivatives in vitro diagnostic products nonbiological products for laboratories and hospitals revenue € million  € million   operating income € million  € million   profit € million  € million  total assets € million  € million  total equity € million  € million  number of employees   average   average website wwwgrifolscom grifols sa catalan ɡɾiˈfɔɫs is a european multinational pharmaceutical and chemical company from catalonia principally a producer of blood plasmabased products a field in which it is the european leader and largest worldwide the company also supplies devices instruments and reagents for clinical testing laboratories contents  main products  main operations  ownership  history  references  further reading  external links main productsedit grifols is the major world supplier of ivig albumin factor viii and other plasmaderived products main operationsedit in  the company had  million litres per year of blood fractionation capacity from three plants one at parets del vallès near barcelona in spain  million litres per year another in los angeles  million litres but being expanded to  million litres and a site in clayton nc in the united states the company owns  plasmapheresis centres where it collects around  million litres of plasma per year ownershipedit grifols was listed on the madrid stock exchange in may  the stock became part of the ibex  index in january  historyedit human immunoglobulin for antitetanus use and antithrombin produced by grifols grifols origin lies in the laboratory founded in  in barcelona by dr josé a grifols roig a hematologist and scientist dr grifols was the first researcher to publish the plasmapheresis procedure in  the company introduced its liquid ivig product into the european market in the mids probitas pharma sa was incorporated with high limited liability under spanish law on  june  on  june  the company changed its name to grifols sa in  the company acquired certain assets of the los angelesbased alpha therapeutic us subsidiary of mitsubishi pharma as the basis of its american expansion on may   grifols securities were listed on spain’s mercado continuo in  csl limited attempted to takeover talecris biotherapeutics the former plasma business of bayer healthcare llc biological products division for  billion but was stopped by the federal trade commission on june   a year after announcing the  billion deal grifols completed a takeover of talecris biotherapeutics headquartered in research triangle park in north carolina with over  employees grifols acquired the blood transfusion diagnostics unit from novartis in  as a platform for global expansion this unit is based in emeryville california and was a part of chiron acquired by novartis in  in  the company acquired a  stake in alkahest as part of planned codevelopment of plasmabased products for the treatment of cognitive decline in aging and disorders of the cns including alzheimers in december  grifols acquired hologics interest in their existing joint blood screening unit for  billion referencesedit  a b c d e f group annual consolidated accounts auditors report and directors report for the financial year  grifols retrieved  selfpublished source  smyth sharon gore gareth  june  santander sabadell sol melia urbas iberia preview bloomberg archived from the original on  october  retrieved    a b c staff december  novartis sells blood transfusion dx unit to grifols genetic engineering  biotechnology news paper   p    dowsett sonya  january  blood firm grifols sees  sales up  pct reuters retrieved    grifols sa formerly probitas pharma sa and subsidiaries consolidated annual accounts prepared in accordance with international financial reporting standards as adopted for use in the european union and consolidated directors report  december  retrieved  selfpublished source  mitsubishi pharma to withdraw from us plasma fractionation business as us subsidiary transfers operations press release mitsubishi pharma corporation  april  retrieved    staff  may  news in brief third time lucky for grifols financial news london retrieved    announcing the launch of talecris biotherapeutics press release talecris  april  retrieved  – via businesswire   ftc authorizes suit to stop csls proposed  billion acquisition of talecris biotherapeutics  retrieved    wolf alan m  spanish buyer set to take over talecris news  observer retrieved    staff  april  grifols makes m investment in alkahest news industry watch genetic engineering  biotechnology news paper      httpwwwgenengnewscomgennewshighlightsgrifolsbuyshologicsshareinbloodscreeningunitforb further readingedit httpopenaccessuoceduwebappsobitstreamgrifolsfactorescompetitividadalargoplazopdf external linksedit wikimedia commons has media related to grifols companies portal official website v t e ibex  companies of spain abengoa abertis acs amadeus it group arcelormittal banco bilbao vizcaya argentaria banco popular español banco sabadell banco santander bankia bankinter bolsas y mercados españoles caixabank dia enagás ferrovial fomento de construcciones y contratas gamesa corporación tecnológica gas natural grifols iberdrola inditex indra sistemas international airlines group jazztel mapfre mediaset españa comunicación obrascón huarte lain red eléctrica de españa repsol sacyr vallehermoso técnicas reunidas telefónica viscofan retrieved from httpsenwikipediaorgwindexphptitlegrifolsoldid categories companies listed on nasdaqpharmaceutical companies of spaincompanies established in companies based in barcelonaibex establishments in spaincompanies listed on the madrid stock exchangespanish brandshidden categories accuracy disputes from june pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages catalàdeutschespañolفارسیfrançais edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view grifols  wikipedia grifols from wikipedia the free encyclopedia jump to navigation search grifols sa type sociedad anónima traded as bmad grf nasdaq grfs industry pharmaceuticals chemicals founded  headquarters barcelona catalonia spain key people víctor grifols chairman and ceo products plasma derivatives in vitro diagnostic products nonbiological products for laboratories and hospitals revenue € million  € million   operating income € million  € million   profit € million  € million  total assets € million  € million  total equity € million  € million  number of employees   average   average website wwwgrifolscom grifols sa catalan ɡɾiˈfɔɫs is a european multinational pharmaceutical and chemical company from catalonia principally a producer of blood plasmabased products a field in which it is the european leader and largest worldwide the company also supplies devices instruments and reagents for clinical testing laboratories contents  main products  main operations  ownership  history  references  further reading  external links main productsedit grifols is the major world supplier of ivig albumin factor viii and other plasmaderived products main operationsedit in  the company had  million litres per year of blood fractionation capacity from three plants one at parets del vallès near barcelona in spain  million litres per year another in los angeles  million litres but being expanded to  million litres and a site in clayton nc in the united states the company owns  plasmapheresis centres where it collects around  million litres of plasma per year ownershipedit grifols was listed on the madrid stock exchange in may  the stock became part of the ibex  index in january  historyedit human immunoglobulin for antitetanus use and antithrombin produced by grifols grifols origin lies in the laboratory founded in  in barcelona by dr josé a grifols roig a hematologist and scientist dr grifols was the first researcher to publish the plasmapheresis procedure in  the company introduced its liquid ivig product into the european market in the mids probitas pharma sa was incorporated with high limited liability under spanish law on  june  on  june  the company changed its name to grifols sa in  the company acquired certain assets of the los angelesbased alpha therapeutic us subsidiary of mitsubishi pharma as the basis of its american expansion on may   grifols securities were listed on spain’s mercado continuo in  csl limited attempted to takeover talecris biotherapeutics the former plasma business of bayer healthcare llc biological products division for  billion but was stopped by the federal trade commission on june   a year after announcing the  billion deal grifols completed a takeover of talecris biotherapeutics headquartered in research triangle park in north carolina with over  employees grifols acquired the blood transfusion diagnostics unit from novartis in  as a platform for global expansion this unit is based in emeryville california and was a part of chiron acquired by novartis in  in  the company acquired a  stake in alkahest as part of planned codevelopment of plasmabased products for the treatment of cognitive decline in aging and disorders of the cns including alzheimers in december  grifols acquired hologics interest in their existing joint blood screening unit for  billion referencesedit  a b c d e f group annual consolidated accounts auditors report and directors report for the financial year  grifols retrieved  selfpublished source  smyth sharon gore gareth  june  santander sabadell sol melia urbas iberia preview bloomberg archived from the original on  october  retrieved    a b c staff december  novartis sells blood transfusion dx unit to grifols genetic engineering  biotechnology news paper   p    dowsett sonya  january  blood firm grifols sees  sales up  pct reuters retrieved    grifols sa formerly probitas pharma sa and subsidiaries consolidated annual accounts prepared in accordance with international financial reporting standards as adopted for use in the european union and consolidated directors report  december  retrieved  selfpublished source  mitsubishi pharma to withdraw from us plasma fractionation business as us subsidiary transfers operations press release mitsubishi pharma corporation  april  retrieved    staff  may  news in brief third time lucky for grifols financial news london retrieved    announcing the launch of talecris biotherapeutics press release talecris  april  retrieved  – via businesswire   ftc authorizes suit to stop csls proposed  billion acquisition of talecris biotherapeutics  retrieved    wolf alan m  spanish buyer set to take over talecris news  observer retrieved    staff  april  grifols makes m investment in alkahest news industry watch genetic engineering  biotechnology news paper      httpwwwgenengnewscomgennewshighlightsgrifolsbuyshologicsshareinbloodscreeningunitforb further readingedit httpopenaccessuoceduwebappsobitstreamgrifolsfactorescompetitividadalargoplazopdf external linksedit wikimedia commons has media related to grifols companies portal official website v t e ibex  companies of spain abengoa abertis acs amadeus it group arcelormittal banco bilbao vizcaya argentaria banco popular español banco sabadell banco santander bankia bankinter bolsas y mercados españoles caixabank dia enagás ferrovial fomento de construcciones y contratas gamesa corporación tecnológica gas natural grifols iberdrola inditex indra sistemas international airlines group jazztel mapfre mediaset españa comunicación obrascón huarte lain red eléctrica de españa repsol sacyr vallehermoso técnicas reunidas telefónica viscofan retrieved from httpsenwikipediaorgwindexphptitlegrifolsoldid categories companies listed on nasdaqpharmaceutical companies of spaincompanies established in companies based in barcelonaibex establishments in spaincompanies listed on the madrid stock exchangespanish brandshidden categories accuracy disputes from june pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages catalàdeutschespañolفارسیfrançais edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view grifols sa  product pipeline review   grifols sa  product pipeline review   grifols sa  product pipeline review   jul    et from reportlinker new york july   prnewswire  summaryglobal markets directs grifols sa  product pipeline review   provides an overview of the grifols sas pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of grifols sas complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of grifols sa including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of grifols sas human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the grifols sas pipeline productsreasons to buy evaluate grifols sas strategic position with total access to detailed information on its product pipeline assess the growth potential of grifols sa in its therapy areas of focus identify new drug targets and therapeutic classes in the grifols sas rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of grifols sa and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of grifols sa develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of grifols sa and identify potential opportunities in those areas avoid intellectual property rights related issuesread the full report httpwwwreportlinkercompsummaryviewreporthtmlabout reportlinker reportlinker is an awardwinning market research solution that finds filters and organizes the latest industry data so you get all the market research you need  instantly in one placehttpwwwreportlinkercom contact clare clarereportlinkercom us intl   source reportlinker related links httpwwwreportlinkercom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more my news release contains wide tables view fullscreen read more jul    et global colorectal cancer partnering  to  jul    et global organic acid market by type acetic acid citric acid jul    et pharmacy automation market by product packaging  labeling looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search grifols united states  our products javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand united states   home   products   us corporate responsibility   news and events   contact europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world pioneering spirit united states home products us corporate responsibility news and events contact europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world united states  home  our products our company our products our leadership our patients our donors our products globally grifols develops and produces more than a dozen plasmaderived protein therapies as well as products and iv solutions designed for hospital pharmacies hospitals and laboratories our wide range of therapies and products are distributed through three primary divisions bioscience diagnostic and hospital bioscience as our largest segment of the business the bioscience division is committed to discovering developing and producing plasmaderived protein therapies to treat patients whose diseases in many cases cannot be adequately treated with traditional pharmaceuticals the essential proteins found in human plasma are used to replace or restore missing proteins among patients who have rare genetic diseases such as immune deficiencies autoimmune disorders bleeding or bloodclotting disorders and genetic emphysema our protein therapies are also administered to prevent the onset of lifethreatening infections such as rabies hepatitis and tetanus bioscience products are sold in more than  countries worldwide diagnostic our diagnostic division focuses on researching developing manufacturing and marketing in vitro diagnostic products for laboratory analyses including autoanalyzers and reagents for hospital blood banks and transfusion centers these innovative diagnostic solutions are sold in the us and more than seventy other countries worldwide hospital our hospital division supplies a wide range of intravenous solutions for hospital pharmacies and medical devices for surgical procedures  these products are divided into four specialties – iv therapy clinical nutrition hospital logistics and medical devices – and are available in some european and latin american countries   intended for unted states audiences only × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info grifols united states  our company javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand united states   home   products   us corporate responsibility   news and events   contact europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world pioneering spirit united states home products us corporate responsibility news and events contact europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world united states  home  our company our company our products our leadership our patients our donors our company our company at grifols we take pride in our innovative achievements strong customer service sterling safety record and adherence to the highest standards of honesty and professional ethics we have an unwavering commitment to the development of safer and more effective blood and plasma therapies as well as innovative products designed for hospitals laboratory professionals and healthcare providers our company develops and produces therapies and products in three healthcare divisions bioscience therapies made from human plasma hospital products and pharmacy iv solutions and diagnostic tools for laboratory professionals our us presence grifols has a strong presence in the united states where our products and therapies are widely distributed we own and operate  plasma donor centers where we collect plasma from qualified individuals and send it to one of our three stateoftheart manufacturing facilities there specialized engineers and technicians are responsible for extracting fragile proteins from plasma and purifying them for use in one of our many protein therapies our manufacturing sites are located in clayton north carolina los angeles california and melville new york our history the inspiration for presentday grifols began in  in barcelona spain in the pioneering research laboratories of hematologist dr jose antonio grifols roig dr grifols and his two sons incorporated laboratorios grifols in  to advance their work in the developing fields of transfusion blood banking and clinical analysis the laboratory focused its research on improving the process of blood transfusions and creating tools for clinical analysis in  the laboratory began researching the potential applications of lyophilization or freezedrying and as it related to human blood products such as plasma grifols patented this process in spain and developed a lyophilizer as well as instrumentation to later inject this plasma into people these products laid the foundations for the opening of the first private blood bank in spain in  in  grifols registered a patent on a new glucosaline solution and the company began industrial production on its first line of iv products innovations at grifols we approach challenges and opportunities with the eyes of experience as well as through a fresh perspective that considers new ways of solving old problems we combine experience flexibility and original thinking to arrive at innovative solutions for patients hospitals and healthcare professionals grifols sustains a full and active research and development program that has acquired more than  patents in over  countries for plasmaderived therapies alone and some  official product registrations in more than  countries grifols serves healthcare professionals and patients in over  countries around the world our innovative spirit has led to the formation of our own engineering and design group that has custom designed machines and facilities for both grifols and other biopharmaceutical companies throughout the world our plasma screening processes were the first approved by the fda to use nucleic amplification testing methods — a process that not only detects a whole virus but can also detect noninfectious virus fragments our fdaapproved manufacturing facilities are among the most modern in existence and compare favorably with biological plants anywhere in the world   intended for unted states audiences only × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world grifols worldwide  serving people’s health javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world pioneering spirit choose country europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world worldwide  about grifols  serving people’s health serving people’s health bioscience diagnostic hospital grifols spirit our production area our origins corporate responsibility where to find us serving peoples health grifols is a global healthcare company whose mission is to improve the health and well being of people around the world we accomplish this mission by producing lifesaving protein therapies for patients and by providing hospitals pharmacies and healthcare professionals with the tools they need to deliver expert medical care we have three primary divisions  bioscience diagnostic and hospital – which develop produce and market our innovative products and services to medical professionals in more than  countries around the world   the information contained on the grifols worldwide website is not applicable to all countries for specific information on the products available in your country please select your country from the list at the top of the page × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world grifols worldwide  welcome javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world the same commitment and innovation as the first day researching new medical solutions for hospitals delivering health solutions since  choose country europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world corporate news grifols increases its revenues by  to eur  million driven by growth of its main divisions first half of  results  info winner of the  spin award program grifols scientific awards  info grifols opens new lines of research with the acquisition of a  stake in gigagen for usd  million grifols strengthens its rdi through investee companies  info highlights manufacturing we are a solid company with an international dimension choosediagnostic grifolsgrifols engineeringinstituto grifols and grifols biologicalsbiomatgrifols plasma operationslaboratorios grifols corporate commitment we contribute to improving peoples health and wellbeing by offering safe high quality products produced using the latest environmentally friendly technology chooseenvironmentvictor grifols foundationannual report grifols academy  when a dream comes true an illustrated history of  years of grifols read when a dream comes true an illustrated history of  years of grifols to discover the companys roots and learn more about our history and the development of the company   info     the information contained on the grifols worldwide website is not applicable to all countries for specific information on the products available in your country please select your country from the list at the top of the page × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world grifols united states  home javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand united states   home   products   us corporate responsibility   news and events   contact europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world pioneering spirit united states home products us corporate responsibility news and events contact europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world united states  home our company our products our leadership our patients our donors grifols usa from our family to your family a heritage of caring grifols is a global healthcare company whose mission is to improve the health and well being of people around the world we accomplish this mission by producing lifesaving protein therapies for patients and by providing hospitals pharmacies and healthcare professionals with the products they need to deliver expert medical care grifols has been working in the fields of transfusion blood banking protein therapeutics and laboratory analysis for more than  years founded in  by dr ja grifols roig three generations of the grifols family have led the company ever since today our grifols sa president victor grifols ensures that the company remains focused on what matters most people our dedication to the advancement of healthcare for humankind is evidenced by our strong global presence we distribute products in  countries plasma safety   news grifols increases its revenues by  to eur  million driven by growth of its main divisions first half of  results  info winner of the  spin award program grifols scientific awards  info grifols opens new lines of research with the acquisition of a  stake in gigagen for usd  million grifols strengthens its rdi through investee companies  info grifols voluntarily discloses transfers of value the company adopted the efpia code of conduct in   info araclon biotech initiates phase ii clinical trials of its alzheimers vaccine after receiving approval from the spanish agency of medicinal products and medical devices  info grifols awards one million dollar grant to support the alpha foundations john w walsh research fund honoring the memory of john w walsh cofounder of the alpha foundation  info grifols continues to strengthen its diagnostic division by launching new global testing services for the measurement of biological drug levels and antidrug immune response in blood samples grifols launches new therapeutic drug monitoring testing services for the biologic drugs infliximab adalimumab and vedolizumab  info grifols and beckman coulter enter into an exclusive distribution agreement multiyear agreement advances companies objectives to provide diagnostics solutions that support and improve patient care  info grifols physiological saline solution produced in its murcia facility receives us fda approval grifols hospital division gains momentum in the us  info grifols allocates euros  million to dividends with a compound annual growth rate of  over the last  years grifols holds its ordinary annual general shareholders meeting with more than  of its share capital represented  info grifols makes procleix zika virus assay available for screening blood donations to countries accepting ce mark grifols strengthens its procleix portfolio with the ce marking for procleix zika virus assay  info investigational new drug application is now effective for babesia screening in blood donations using grifols procleix panther system in the us fda has allowed the use of the test under an investigational new drug ind study for selected blood banks in the us  info bioscience division sales increase  to drive grifols revenue growth by  to euros  million first quarter  results  info grifols strengthens position as global provider of diagnostic testing solutions with fiveyear extension of orasure technologies agreement and a new manufacturing facility longstanding relationship between companies fortified by multiyear contract extension  info grifols donates  million international units of blood clotting factors to the world federation of hemophilia humanitarian aid program helping treat tensofthousands of patients in developing countries renewing partnership with wfh reaffirming commitment to improving the lives of patients around the world  info the president of the company víctor grífols roura honored with the distinction creu de sant jordi the creu de sant jordi one of the highest honors awarded by the government of catalonia  info grifols participates at the rd international conference on research into alpha antitrypsin deficiency and the th international congress of alpha patients patients and researchers from across the world are meeting to discuss the latest scientific advances in alpha antitrypsin deficiency a rare genetic disease that can cause respiratory illness particularly emphysema  info grifols revenues exceed euros  million driven by  growth of the bioscience division annual results   info grifols refinances debt for usd  billion reducing the margin to  bps and extending its maturities the company has concluded its debt refinancing process substantially improving all conditions  info grifols closes the acquisition of hologics share of nat donor screening unit for usd  million the company consolidates a leading position of its diagnostic division enhancing its integration  info grifols agrees to acquire hologics share of nat donor screening unit for usd  million the company consolidates a leading position of its diagnostic division enhancing its integration  info sales of the bioscience division grow by  increasing grifols revenues to eur  million results for the nine months ended september   info grifols relocates its headquarters in germany to a new office building grifols has a commercial subsidiary in germany since  and following the acquisition of talecris in  the country also hosts the commercial headquarters of the bioscience division in europe  info grifols opens diagnostic training center in dubai the new center part of grifols growing diagnostic business will train laboratory technicians engineers and specialists on grifols systems and laboratory best practices  info grifls supports the canadian blood services missing type campaign grifls is proud to support the canadian blood services missing type campaign this is a global campaign whose goal is to increase the number of new registered blood donors in the last decade there has been a downward trend of new registered blood donors which may put the blood supply at risk  info the results of phase i clinical trial of the araclon biotech alzheimers vaccine support its continuation the conclusions of the trial were presented at the alzheimers association international conference in toronto the compound abvac designed to combat alzheimers disease at its initial stage has demonstrated a good safety and tolerability profile  info sales of the bioscience division grow by  increasing grifols revenues by  to eur  million results for the first half of   info award winners of the th annual martín villar haemostasis awards the awards ceremony was held at the symposium organized by grifols at the wfh world congress in orlando on july    info grifols agrees to acquire a  sq ft plot of land to expand its production facilities in barcelona spain the plot is located in the spanish town of lliçà de vall a future industrial park adjacent to the industrial park of llevant of parets del vallès where currently grifols has production facilities  info pedigri® the tool that increases the information transparency to the plasmaderived manufactured in clayton gammastan® gamunex®  gamunexc® hyperhep b® hyperrab® hyperrho® hypertet® koāte® dvi plasbumin® prolastin®  prolastin® c and thrombate® iii are the newly added products  info award winner of the  spin awards program created in  the spin awards program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology  info fda approves use of the procleix zika virus assay from hologic and grifols to screen the us blood supply under an ind study protocol blood banks will use the new test codeveloped by hologic and grifols to screen donated blood in potential endemic areas of the us  info grifols allocates eur  million to dividends and maintains payout at  of consolidated net profit grifols ordinary general meeting of shareholders  info sippet an international randomized study reports  higher incidence of inhibitors with recombinant factor viii in patients with severe hemophilia a results of the study have just been published in the may th issue of the new england journal of medicine  info grifols revenues increase by  to euros  million driven by growth of  for the bioscience division the company has announced a new industrial expansion plan and continues with its initiatives to increase access to plasma  info the catalan downs syndrome foundation and grifols are working together to promote research grifols has donated  euros to support the foundations research effort designed to improve the quality of life of people with intellectual disability  info lurie childrens hospital selects grifols kiro® robot to increase precision safety and compliance of pediatric iv chemotherapy handling and compounding grifols kiro robotic system provides nextgeneration precision and automation for sterile compounding of iv medications  info the company doesn´t have any tax litigation in any country where it operates because of the dissemination of some information with regard the grifols sa  consolidated annual accounts filed with the cnmv last monday the company would like to clarify the following points  info grifols revenues grow by  to euros  million and net profit grows by  reaching euros  million grifols mce grf mce grfp and nasdaq grfs reported net revenues of euros  million for  growing  compared to euros  million reported in  exchange rates movements in particular of the us dollar had a positive impact on revenues that grew  at constant currency cc  info grifols invests in the project led by albajuna therapeutics a spinoff from irsicaixa to fund the development of therapeutic antibodies against hiv albajuna therapeutics a spinoff from the irsicaixa aids research institute is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize hiv and activate the natural killer cells responsible for destroying cells infected by the virus  info grifols obtains exclusive rights to market and distribute massbiologics tetanus and diphtheria toxoids adsorbed td vaccine in us almost all cases of tetanus in the us occur in people who have never been immunized or who have not had a tetanus booster shot within the preceding  years  info grifols makes public its succession plan the envisaged generational handover reiterates the commitment of the founding family to the company from  january  victor grifols roura will be succeeded by his brother raimon grifols and his son víctor grifols deu who will become joint and several chief executive officers of the company víctor grifols will continue holding his position as nonexecutive chairman of the board of directors  info the sippet study on inhibitors in hemophilia a reports a higher incidence of inhibitors with recombinant factor viii than plasmaderived factor viii containing von willebrand factor the results may have implications in the choice of products for management in previously untreated patients pups with severe hemophilia a  info inauguration of the grifols chair for the study of cirrhosis the grifols chair for the study of cirrhosis a private chair with an international reach was created to promote research and education on liver diseases especially cirrhosis  info the intermediate results from the grifols ambar study support its continuation the intermediate results show the tolerability and safety of the treatment  info grifols agrees long term loan with the european investment bank grifols is one of the first companies to receive funding from the european investment bank eib through the new european fund for strategic investments efsi  info grifols official opening of the bioscience division new worldwide operations facility in ireland total investment in the project reaches  million dollars and is a fundamental part of grifols growth strategy  info grifols announces the  alta award winners during the ers congress in amsterdam the annual alta award sponsored exclusively by grifols provides two fellowships of € to young investigators and clinicians whose work contributes to the understanding and treatment of alphaantitrypsin deficiency aat deficiency  info grifols antithrombin research awards gatra program  on october th the ceremony for the first edition of the gatra program grifols scientific awards about research on antithrombin was held at the museu grifols in barcelona  info albumin awards program albus  berlin held the ceremony of the first edition of the albus awards  info spin award program  the spin award program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology  info award winners at the th annual martín villar haemostasis awards  info dr víctor grífols i lucas – dr víctor grífols i lucas passed away in barcelona on june the st   info grifols a healthcare company participates in white house upskill summit grifols a global leader in the production of plasmaderived medicines participated in the white house summit on employee upskilling  info alphanate® antihemophilic factorvon willebrand factor human is the preferred pdfviii product for the treatment of hemophilia a among hematologists practicing in an htc alphanate is physician preferred  info grifols to make a major equity investment in alkahest alkahest is a company founded in  by leading scientists who demonstrated at stanford university us that factors in the blood of young animals were able to restore mental capabilities in old animals  info grifols achieves a record net profit of  million euros with growth of  in  grifols net revenues rose by  to  million euros  info grifols phocusrx certified diacap compliant the phocusrx system can operate with a low and acceptable level of risk when installed in a department of defense facility that meets security requirements  info sippet study on inhibitors in hemophilia a interim analysis confirms the original hypothesis the study is safe to continue after investigators meeting and the disclosure of interim analysis in san francisco  info grifols partners with johnston county educators to develop science program discover the plasma program will enhance the eighth grade curriculum in johnston county middle schools and raise awareness about lifesaving plasma therapies  info grifols academy of plasmapheresis awarded accet accreditation grifols a global leader in the production of plasmaderived medicines is pleased to announce that its academy of plasmapheresis has been awarded accreditation by the accrediting council for continuing education and training accet  info grifols receives fda approval for its new purification plant to produce gamunex in los angeles the plant located in los angeles california represents an investment of  million euros and over  new jobs will be created when it starts operation in   info grifols contributes to river restoration projects restoring the course of the river tenes and a study of the reintroduction of otters are the focus of a cooperation agreement with the consortium for the protection of the river besós basin  info grifols introduces new g ivig vial size for gamunexc the widest range of vial sizes expands convenience options for ig therapy  info investigating inhibitor development in patients with hemophilia a lecture on stateoftheart of the sippet study presented by pm mannucci sponsored by grifols kedrion and lfb  info grifols presents its gatra scholarship program to promote research on antithrombin therapy the gatra program grifols antithrombin research awards was announced on october  world thrombosis day and grants two yearly scholarships of  euros each for a month period of research  info grifols reinforces its commitment to research in the th edition of the martín villar awards for research on hemostasis created in  the awards recognize progress made in the field of hemostasis the awards are endowed with  euros for each of the two prizes basic research and clinical research  info grifols acquires  of the share capital of kiro robotics for  million euros grifols strengthens its commitment to research and promotes the international growth of its hospital division  info grifols achieves ten years of research into alzheimers in the last decade the company has developed a comprehensive strategy for research into the disease and currently has three clinical trials underway  info new highly sensitive test to screen donors of blood tissues and organs for hepatitis e virus receives ce mark the test which uses nucleic acid technology nat to detect hepatitis e virus will run on the fully automated procleix®panther®system in the eu  info award winners at the seventh edition of the martín villar research awards martín villar research awards   info grifols launches a continuing education program for transfusion medicine professionals in the united states the program is designed to update knowledge and share advances in the field of transfusion safety  info grifols opens stateoftheart facility in clayton nc to help advance treatment of rare and lifethreatening diseases grifols north fractionation facility will be the worlds largest and one of the most technologically advanced plasma fractionation facilities increasing production capacity in clayton from  million liters of plasma annually to  million liters in   info grifols announces availability in europe of alphakit®quickscreen a novel pointofcare screening device to aid in the detection of alphaantitrypsin deficiency aatd alphakit® quickscreen is a novel pointofcare immunochromatographic in vitro diagnostic screening test for the zform of alphaantitrypsin zaat  info grifols fractionation facility in clayton receives the ispe  facility of the year award the international society for pharmaceutical engineering awarded the prize to the north fractionation facility in the category for project execution  info grifols los angeles site is awarded highly protected risk hpr status the hpr award recognizes the highest level asite can achieve in terms of prevention and protection  info grifols celebrates world hemophilia day with donation of coagulation medicines to the world federation of hemophilia threeyear commitment of up to  million units per year of blood clotting medicines to treat hemophilia patients in developing countries  info grifols opens new plasma fractionation plant in spain the company has invested over  million euros doubling its plasma fractionation capacity in spain  info japanese red cross selects grifols as partner for nucleic acid screening of nations blood supply japanese red cross will use the procleix® panther® platform to screen approximately  million blood donations each year for hiv and hepatitis viruses  info grifols sales rose by  to euros  million in  grifols maintained its position as the third largest producer of plasma derivatives  info grifols opens new head office of araclon biotech in zaragoza spain araclon is an rd company specializing in immunotherapy and diagnosis of alzheimers and other degenerative diseases  info vall dhebron research institute vhri collaborates with grifols to create a center of excellence for research into alpha antitrypsin deficiency the aim of the project is to improve our understanding of patients with alphaantitrypsin deficiency  info the fundació ace with the support of grifols opens a new center for the treatment and research of alzheimers disease the barcelona alzheimer treatment  research center is operated by fundació ace as an independent center with the aim of facilitating the diagnosis and treatment of alzheimers and other neurodegenerative diseases and promoting biomedical research into these conditions  info grifols signs an agreement with cumberland pharmaceuticals to market ibuprofen for intravenous infusion impulses the international growth strategy of the hospital division  info grifols contributes to transfusion medicine education with the third edition of the transfusion science educational course grifols delivers a number of courses each year to help train and advance the careers of transfusion medicine professionals who in turn ensure the quality and safety of the blood transfusions  info grifols announces launch of the spirit registry at the nhf annual meeting grifols inc a leading manufacturer of lifesaving plasmaprotein therapies today announced the launch of the spirit study of plasmaderived factor viiivwf in immune tolerance induction therapy  info grifols introduces the alphakitreg quickscreen a novel pointofcare screening device to detect alphaantitrypsin aat deficiency a leading cause of genetic emphysema  copd in adults details presented at the annual congress of the european respiratory society ers  info grifols announces winners of the th annual ealta research fellowship at  ers congress awards fund early career investigators research to advance understanding and treatment of alphaantitrypsin deficiency  info grifols takes part in the exhibition molecules of life  years of biochemistry and molecular biology in spain grifols sponsors the module dedicated to plasma proteins which consists of an augmented reality system  info grifols implements its first automated inventory management carousel system for investigational pharmacies at emory university the first automated inventory management carousel has been implemented at emory university investigational drug service  info grifols increases its collaboration with the chronic liver failure european consortium the company will contribute three million euros over the next four years in addition to the two million committed since   info award winners at the sixth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways does this is through the martín villar awards for research into haemostasis  info grifols announces transfer of management of melville new york plasma fractionation facility to kedrion today grifols sa grifols announced that effective july   it will transfer management of the melville  info grifols study demonstrates higher dose of prolastinc increases levels of alphapi to within normal range in patients with aat deficiency study results presented at annual meeting of american thoracic society ats  info grifols officially inaugurates new immunoglobulin plant in the united states ivigs are the most important and most widely consumed plasma derived protein therapies  info cadence pharmaceuticals entrust grifols the manufacturing of ofirmev® paracetamol injection in flexible iv bags manufacturing and supply agreement between cadence pharmaceuticals and grifols  info grifols inaugurates the extension to its production facilities in las torres de cotillas murcia the project involved a total investment of  million euros  info grifols announces first patient enrolled and dosed in phase ii trial of alpha hc aerosol to treat cystic fibrosis the multicenter trial will investigate two doses of alpha hc aerosol an inhaled formulation of grifols alphaproteinase inhibitor human  info grifols alzheimer research strategy addresses the degenerative disease from a global perspective the company presented its research projects to coincide with world alzheimers day held on september   info grifols agrees to purchase three plasma donation centers in the united states from canadas cangene once the transaction is concluded grifols has  plasmapheresis centers  info grifols awards winners of the th annual ealta research fellowship at  ers meeting awards fund earlycareer investigators research to advance understanding and treatment of alphaantitrypsin deficiency  info araclon biotech has identified a new blood protein with diagnostic value for alzheimers disease the spanish biotech firm in which grifols has a majority shareholding has presented the first results at the alzheimers association international conference in vancouver canada  info grifols acquires  of the capital of biotechnology firm vcn bioscience the groups investment will ensure the viability of research projects in the field of oncology  info award winners at the fifth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways does this is through the martín villar awards for research into haemostasis  info grifols launches ambar study based on the combined use of plasma derivatives and plasmapheresis to treat alzheimers disease the new ambar study combines therapeutic plasmapheresis with alternating infusion of albumin and intravenous immunoglobulin ivig to treat alzheimers  info grifols is to construct a plant in brazil to manufacture bags for the extraction and conservation of blood components the group has strengthened its manufacturing presence in latin america  info grifols continues to contribute to transfusion medicine training with its second european edition of the transfusion science education course each year grifols holds a number of courses intended to provide an opportunity for transfusion medicine professionals to learn and progress through training we can ensure the quality and safety of the transfusions that millions of people throughout the world receive each year  info grifols extends its commitment to scientific dissemination with a new publication perspectives in transfusion medicine the twiceyearly publication is a means of distributing scientific content developed by leading researchers in the field of transfusion medicine  info grifols opens new state of the art plasma testing laboratory in san marcos the squarefootfacility will create new jobs as well as provide job opportunities for existing grifols employees through consolidation of the companys plasma testing operations at the new san marcos facility and an existing facility in austin texas  info pau gasol introduces new technology donated by grifols to pharmacy at childrens hospital los angeles new equipment designed to enhance safety and efficiency by automating quality control oversight during compounding of medications  info grifols sales increase by  in constant currency terms in  to  millon euros grifols leads global sales of ivig and ap used to treat pulmonary emphysema after talecris acquisition  info award winners at the fourth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways is does this is through the martín villar awards for research into hemostasis  info grifols inaugurates its global headquarters in barcelona  info grifols´ sales grow  to  million euros in the first quarter of  strong growth in the united states where sales increased by  during the quarter higher sales volumes of plasma derivatives such as ivig and factor viii confirm the upward trend in the sector  info grifols establishes expert advisory council in transfusion medicine the role of the expert advisory council is to provide insight advice and guidance to grifols´own transfusion medicine research and development activities  info fda approves revised alphanate® labeling to include reduced infectivity of an experimental model agent for vcjd alphanate® será el primer factor de coagulación sanguínea hemoderivado en incluir en su etiquetado información sobre procesos de fabricación que ofrecen una garantía razonable de eliminación de bajos niveles de un agente considerado modelo de la vecj  info grifols signs cooperative agreement for commercialization of immunohematology diagnostic products in the us agreement will facilitate access to stateoftheart immunohematology products to blood banks and hospitals transfusion centers in the us  info grifols starts construction of a new plasma fractionation plant in parets del vallès the new facilities will deliver up to an additional maximum of two million liters of plasma fractionation capacity in spain raising total capacity from the current figure of  million liters to  million liters  info grifols expands its patientcare program to address insurance lapses in the primary immune deficiency community as part of its ongoing commitment to the primary immune deficiency community grifols offers its ivig therapies at no cost to those who have a lapse in insurance or are in need of temporary assistance  info grifols expands its patientcare program to address insurance lapses in the primary immune deficiency community as part of its ongoing commitment to the primary immune deficiency community grifols offers its ivig therapies at no cost to those who have a lapse in insurance or are in need of temporary assistance  info grifols announces us launch of flebogamma®  dif ivig building on the safety record of its  concentration the new  liquid room temperature ivig preparation establishes grifols as the only producer offering both  and  ivig concentrations to healthcare providers and patients in the us  info grifols announces us launch of flebogamma®  dif ivig building on the safety record of its  concentration the new  liquid room temperature ivig preparation establishes grifols as the only producer offering both  and  ivig concentrations to healthcare providers and patients in the us  info grifols updates the pedigri® website as of today pedigri® has a new website at the following address wwwpedigrigrifolscom  info grifols´ turnover increased by  in the first nine months of  to  mm grifols reaches its highest quarterly turnover exceeding  million euros between july and september  in the third quarter the bioscience division grew by  mainly driven by the us market the higher sale volumes of plasma derivatives such as albumin and ivig with doubledigit increases confirm the upward trend of the sector recurrent ebitda of the business grew by  up to  million euros net profit at  million euros falls by  due to costs associated with the corporate transaction and higher financial expenses  info grifols continues investing to boost its diagnostics division a new plant will produce the mdmulticard® for the rapid determination of blood groups expanding grifols´offer in transfusion diagnostics investment made in production facilities in australia and switzerland amounts to  million euros  info progenika biopharma grants grifols worldwide distribution of its bloodchip® genotyping test for blood donors the spanish biotechnology company progenika biopharma is a pioneer in the development of molecular biology tests for blood transfusion compatibility the bloodchip® global distribution agreement strengthens grifols´the diagnostic division and is expected to generate revenues of between  million over the next  years bloodchip® assures the global reach of the test  info grifols to acquire talecris biotherapeutics creating a world leading provider of lifesaving plasma protein therapies the combination of grifols and talecris will create a diversified global provider of lifesaving and life enhancing plasma protein therapeutics built on the strong global presence of grifols and the established position of talecris in the united states and canada the merger accelerates key strategic initiatives for both talecris and grifols as it creates a more efficient platform for manufacturing innovation and global sales and marketing combining the expertise of both companies will build upon their individual legacies of patient commitment growth and innovation while increasing the availability of high quality plasma protein therapies for patients worldwide  info grifols introduces mixvial™ filter transfer sets a new needlefree transfer set will add to patient convenience and ease of use when reconstituting grifols coagulation therapies  info grifols introduces mixvial™ filter transfer sets a new needlefree transfer set will add to patient convenience and ease of use when reconstituting grifols coagulation therapies  info moving forward in safety grifols introduces a holographic seal on its plasma derivative packaging the holographic seal on its plasma derivative packaging is a an additional measure adopted by grifols in its commitment to giving its products the highest levels of safety  info fundación probitas provides aid for haitian population fundación probitas which was created in  under the auspices of grifols has now started to operate and as its first action has approved emergency aid for the haitian population  info grifols obtains fda approval for new sterile albumin filling plant in los angeles grifols has received approval from the fda for its new sterile albumin filling plant in los angeles this approval is the culmination of a threeyear project to transform the entire process of obtaining purifying and filling albumin vials at grifols biologicals inc los angeles  info grifols publishes interim results of its clinical trial on alzheimers disease the preliminary results of the trial suggest that patients who received treatment showed a trend towards stabilization of the disease the line of investigation was based on the systematic practice of therapeutic plasmapheresis with human albumin grifols in patients with this disease  info work recognised in the nd edition of the martín villar haemostasis awards researcher giancarlo castaman wins first prize for his study into the response of von willebrand patients to treatment with desmopressin  info the annual martin villar haemostasis awards is open to applications el plazo de presentación de candidaturas a los premios martín villar se ha abierto oficialmente con dotaciones económicas que suman un total de  euros para los trabajos ganadores  info grifols promotes european research into liver cirrhosis the european consortium for the study of chronic liver failure created today brings together  centres from across europe and will be coordinated from barcelona´s hospital clínic by professor vicente arroyo  info new method makes it possible to transport medicine cells to areas affected by inflammatory processes this discovery the product of collaboration between research centres and the grifols group of companies is a step towards what has been described as the medicine of the future personalized therapy  info grifols academy of plasmapheresis opens in us based in arizona in the united states the initiative reflects a firm commitment to employee training and knowledge sharing in line with the degree of specialisation required in the plasma derivative industry  info grifols gets a minority stake in cardio biosciences founded by a group of scientists from the cardiovascular center in aalst belgium on a technology developed by researchers at mayo clinic cardio biosciences specialises in stemcell based biotherapeutic rd for the treatment of cardiovascular diseases  info the martin villar haemostasis awards ceremony held in barcelona established by grifols in  these awards pay tribute to the worldrenowned hematologist martín villar and promote research in hemostasis by recognizing the most outstanding basic or clinical research projects on blood coagulation disorders  info grifols presents blispack® an automated blister identification and opening tool for medications in the hospital blispack® was launched at the rd national congress of the hospital pharmacy spanish society in valencia october  to   info grifols acquires office complex in sant cugat the new complex will allow the grifols group to centralize its shared corporate areas while also providing space for future growth these areas are currently based in rented office space primarily in barcelona and without any scope for physical expansion  info grifols breaks ground on new ivig facility the new facility based in los angeles california is anticipated to be operational in  and will expand the companys ability to supply its new generation of intravenous immune globulin into the foreseeable future  info grifols breaks ground on new ivig facility the new facility based in los angeles california is anticipated to be operational in  and will expand the companys ability to supply its new generation of intravenous immune globulin into the foreseeable future  info final stage of implementation of pedigri® on line extends transparency of information to all grifols plasma derivatives grifols has extended pedigri® on line to all of its plasma derivatives including albutein® alphanate® alphanine® and profilnine® sd also as part of the final stage the company has officially launched pedigri® on line in the us market  info grifols obtains fda licence for new filling area at its plasma products plant in the usa the new facilities ensure maximum safety for the sterile filling and lyophilization of grifols coagulation factors the fact that the licence was awarded within  months reflects the company´s experience and reputation in regulatory affairs with the fda  info cardinal health and grifols concluded an exclusive  year distribution agreement cardinal health and grifols concluded an exclusive  year distribution agreement  info grifols signs agreement with stough development corp to open  new plasma collection centers in the united states as a result the spanish group expects to obtain an additional  of its main raw material without allocating any internal resources to this  info       intended for unted states audiences only × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world grifols united states  home javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand united states   home   products   us corporate responsibility   news and events   contact europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world pioneering spirit united states home products us corporate responsibility news and events contact europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world united states  home our company our products our leadership our patients our donors grifols usa from our family to your family a heritage of caring grifols is a global healthcare company whose mission is to improve the health and well being of people around the world we accomplish this mission by producing lifesaving protein therapies for patients and by providing hospitals pharmacies and healthcare professionals with the products they need to deliver expert medical care grifols has been working in the fields of transfusion blood banking protein therapeutics and laboratory analysis for more than  years founded in  by dr ja grifols roig three generations of the grifols family have led the company ever since today our grifols sa president victor grifols ensures that the company remains focused on what matters most people our dedication to the advancement of healthcare for humankind is evidenced by our strong global presence we distribute products in  countries plasma safety   news grifols increases its revenues by  to eur  million driven by growth of its main divisions first half of  results  info winner of the  spin award program grifols scientific awards  info grifols opens new lines of research with the acquisition of a  stake in gigagen for usd  million grifols strengthens its rdi through investee companies  info grifols voluntarily discloses transfers of value the company adopted the efpia code of conduct in   info araclon biotech initiates phase ii clinical trials of its alzheimers vaccine after receiving approval from the spanish agency of medicinal products and medical devices  info grifols awards one million dollar grant to support the alpha foundations john w walsh research fund honoring the memory of john w walsh cofounder of the alpha foundation  info grifols continues to strengthen its diagnostic division by launching new global testing services for the measurement of biological drug levels and antidrug immune response in blood samples grifols launches new therapeutic drug monitoring testing services for the biologic drugs infliximab adalimumab and vedolizumab  info grifols and beckman coulter enter into an exclusive distribution agreement multiyear agreement advances companies objectives to provide diagnostics solutions that support and improve patient care  info grifols physiological saline solution produced in its murcia facility receives us fda approval grifols hospital division gains momentum in the us  info grifols allocates euros  million to dividends with a compound annual growth rate of  over the last  years grifols holds its ordinary annual general shareholders meeting with more than  of its share capital represented  info grifols makes procleix zika virus assay available for screening blood donations to countries accepting ce mark grifols strengthens its procleix portfolio with the ce marking for procleix zika virus assay  info investigational new drug application is now effective for babesia screening in blood donations using grifols procleix panther system in the us fda has allowed the use of the test under an investigational new drug ind study for selected blood banks in the us  info bioscience division sales increase  to drive grifols revenue growth by  to euros  million first quarter  results  info grifols strengthens position as global provider of diagnostic testing solutions with fiveyear extension of orasure technologies agreement and a new manufacturing facility longstanding relationship between companies fortified by multiyear contract extension  info grifols donates  million international units of blood clotting factors to the world federation of hemophilia humanitarian aid program helping treat tensofthousands of patients in developing countries renewing partnership with wfh reaffirming commitment to improving the lives of patients around the world  info the president of the company víctor grífols roura honored with the distinction creu de sant jordi the creu de sant jordi one of the highest honors awarded by the government of catalonia  info grifols participates at the rd international conference on research into alpha antitrypsin deficiency and the th international congress of alpha patients patients and researchers from across the world are meeting to discuss the latest scientific advances in alpha antitrypsin deficiency a rare genetic disease that can cause respiratory illness particularly emphysema  info grifols revenues exceed euros  million driven by  growth of the bioscience division annual results   info grifols refinances debt for usd  billion reducing the margin to  bps and extending its maturities the company has concluded its debt refinancing process substantially improving all conditions  info grifols closes the acquisition of hologics share of nat donor screening unit for usd  million the company consolidates a leading position of its diagnostic division enhancing its integration  info grifols agrees to acquire hologics share of nat donor screening unit for usd  million the company consolidates a leading position of its diagnostic division enhancing its integration  info sales of the bioscience division grow by  increasing grifols revenues to eur  million results for the nine months ended september   info grifols relocates its headquarters in germany to a new office building grifols has a commercial subsidiary in germany since  and following the acquisition of talecris in  the country also hosts the commercial headquarters of the bioscience division in europe  info grifols opens diagnostic training center in dubai the new center part of grifols growing diagnostic business will train laboratory technicians engineers and specialists on grifols systems and laboratory best practices  info grifls supports the canadian blood services missing type campaign grifls is proud to support the canadian blood services missing type campaign this is a global campaign whose goal is to increase the number of new registered blood donors in the last decade there has been a downward trend of new registered blood donors which may put the blood supply at risk  info the results of phase i clinical trial of the araclon biotech alzheimers vaccine support its continuation the conclusions of the trial were presented at the alzheimers association international conference in toronto the compound abvac designed to combat alzheimers disease at its initial stage has demonstrated a good safety and tolerability profile  info sales of the bioscience division grow by  increasing grifols revenues by  to eur  million results for the first half of   info award winners of the th annual martín villar haemostasis awards the awards ceremony was held at the symposium organized by grifols at the wfh world congress in orlando on july    info grifols agrees to acquire a  sq ft plot of land to expand its production facilities in barcelona spain the plot is located in the spanish town of lliçà de vall a future industrial park adjacent to the industrial park of llevant of parets del vallès where currently grifols has production facilities  info pedigri® the tool that increases the information transparency to the plasmaderived manufactured in clayton gammastan® gamunex®  gamunexc® hyperhep b® hyperrab® hyperrho® hypertet® koāte® dvi plasbumin® prolastin®  prolastin® c and thrombate® iii are the newly added products  info award winner of the  spin awards program created in  the spin awards program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology  info fda approves use of the procleix zika virus assay from hologic and grifols to screen the us blood supply under an ind study protocol blood banks will use the new test codeveloped by hologic and grifols to screen donated blood in potential endemic areas of the us  info grifols allocates eur  million to dividends and maintains payout at  of consolidated net profit grifols ordinary general meeting of shareholders  info sippet an international randomized study reports  higher incidence of inhibitors with recombinant factor viii in patients with severe hemophilia a results of the study have just been published in the may th issue of the new england journal of medicine  info grifols revenues increase by  to euros  million driven by growth of  for the bioscience division the company has announced a new industrial expansion plan and continues with its initiatives to increase access to plasma  info the catalan downs syndrome foundation and grifols are working together to promote research grifols has donated  euros to support the foundations research effort designed to improve the quality of life of people with intellectual disability  info lurie childrens hospital selects grifols kiro® robot to increase precision safety and compliance of pediatric iv chemotherapy handling and compounding grifols kiro robotic system provides nextgeneration precision and automation for sterile compounding of iv medications  info the company doesn´t have any tax litigation in any country where it operates because of the dissemination of some information with regard the grifols sa  consolidated annual accounts filed with the cnmv last monday the company would like to clarify the following points  info grifols revenues grow by  to euros  million and net profit grows by  reaching euros  million grifols mce grf mce grfp and nasdaq grfs reported net revenues of euros  million for  growing  compared to euros  million reported in  exchange rates movements in particular of the us dollar had a positive impact on revenues that grew  at constant currency cc  info grifols invests in the project led by albajuna therapeutics a spinoff from irsicaixa to fund the development of therapeutic antibodies against hiv albajuna therapeutics a spinoff from the irsicaixa aids research institute is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize hiv and activate the natural killer cells responsible for destroying cells infected by the virus  info grifols obtains exclusive rights to market and distribute massbiologics tetanus and diphtheria toxoids adsorbed td vaccine in us almost all cases of tetanus in the us occur in people who have never been immunized or who have not had a tetanus booster shot within the preceding  years  info grifols makes public its succession plan the envisaged generational handover reiterates the commitment of the founding family to the company from  january  victor grifols roura will be succeeded by his brother raimon grifols and his son víctor grifols deu who will become joint and several chief executive officers of the company víctor grifols will continue holding his position as nonexecutive chairman of the board of directors  info the sippet study on inhibitors in hemophilia a reports a higher incidence of inhibitors with recombinant factor viii than plasmaderived factor viii containing von willebrand factor the results may have implications in the choice of products for management in previously untreated patients pups with severe hemophilia a  info inauguration of the grifols chair for the study of cirrhosis the grifols chair for the study of cirrhosis a private chair with an international reach was created to promote research and education on liver diseases especially cirrhosis  info the intermediate results from the grifols ambar study support its continuation the intermediate results show the tolerability and safety of the treatment  info grifols agrees long term loan with the european investment bank grifols is one of the first companies to receive funding from the european investment bank eib through the new european fund for strategic investments efsi  info grifols official opening of the bioscience division new worldwide operations facility in ireland total investment in the project reaches  million dollars and is a fundamental part of grifols growth strategy  info grifols announces the  alta award winners during the ers congress in amsterdam the annual alta award sponsored exclusively by grifols provides two fellowships of € to young investigators and clinicians whose work contributes to the understanding and treatment of alphaantitrypsin deficiency aat deficiency  info grifols antithrombin research awards gatra program  on october th the ceremony for the first edition of the gatra program grifols scientific awards about research on antithrombin was held at the museu grifols in barcelona  info albumin awards program albus  berlin held the ceremony of the first edition of the albus awards  info spin award program  the spin award program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology  info award winners at the th annual martín villar haemostasis awards  info dr víctor grífols i lucas – dr víctor grífols i lucas passed away in barcelona on june the st   info grifols a healthcare company participates in white house upskill summit grifols a global leader in the production of plasmaderived medicines participated in the white house summit on employee upskilling  info alphanate® antihemophilic factorvon willebrand factor human is the preferred pdfviii product for the treatment of hemophilia a among hematologists practicing in an htc alphanate is physician preferred  info grifols to make a major equity investment in alkahest alkahest is a company founded in  by leading scientists who demonstrated at stanford university us that factors in the blood of young animals were able to restore mental capabilities in old animals  info grifols achieves a record net profit of  million euros with growth of  in  grifols net revenues rose by  to  million euros  info grifols phocusrx certified diacap compliant the phocusrx system can operate with a low and acceptable level of risk when installed in a department of defense facility that meets security requirements  info sippet study on inhibitors in hemophilia a interim analysis confirms the original hypothesis the study is safe to continue after investigators meeting and the disclosure of interim analysis in san francisco  info grifols partners with johnston county educators to develop science program discover the plasma program will enhance the eighth grade curriculum in johnston county middle schools and raise awareness about lifesaving plasma therapies  info grifols academy of plasmapheresis awarded accet accreditation grifols a global leader in the production of plasmaderived medicines is pleased to announce that its academy of plasmapheresis has been awarded accreditation by the accrediting council for continuing education and training accet  info grifols receives fda approval for its new purification plant to produce gamunex in los angeles the plant located in los angeles california represents an investment of  million euros and over  new jobs will be created when it starts operation in   info grifols contributes to river restoration projects restoring the course of the river tenes and a study of the reintroduction of otters are the focus of a cooperation agreement with the consortium for the protection of the river besós basin  info grifols introduces new g ivig vial size for gamunexc the widest range of vial sizes expands convenience options for ig therapy  info investigating inhibitor development in patients with hemophilia a lecture on stateoftheart of the sippet study presented by pm mannucci sponsored by grifols kedrion and lfb  info grifols presents its gatra scholarship program to promote research on antithrombin therapy the gatra program grifols antithrombin research awards was announced on october  world thrombosis day and grants two yearly scholarships of  euros each for a month period of research  info grifols reinforces its commitment to research in the th edition of the martín villar awards for research on hemostasis created in  the awards recognize progress made in the field of hemostasis the awards are endowed with  euros for each of the two prizes basic research and clinical research  info grifols acquires  of the share capital of kiro robotics for  million euros grifols strengthens its commitment to research and promotes the international growth of its hospital division  info grifols achieves ten years of research into alzheimers in the last decade the company has developed a comprehensive strategy for research into the disease and currently has three clinical trials underway  info new highly sensitive test to screen donors of blood tissues and organs for hepatitis e virus receives ce mark the test which uses nucleic acid technology nat to detect hepatitis e virus will run on the fully automated procleix®panther®system in the eu  info award winners at the seventh edition of the martín villar research awards martín villar research awards   info grifols launches a continuing education program for transfusion medicine professionals in the united states the program is designed to update knowledge and share advances in the field of transfusion safety  info grifols opens stateoftheart facility in clayton nc to help advance treatment of rare and lifethreatening diseases grifols north fractionation facility will be the worlds largest and one of the most technologically advanced plasma fractionation facilities increasing production capacity in clayton from  million liters of plasma annually to  million liters in   info grifols announces availability in europe of alphakit®quickscreen a novel pointofcare screening device to aid in the detection of alphaantitrypsin deficiency aatd alphakit® quickscreen is a novel pointofcare immunochromatographic in vitro diagnostic screening test for the zform of alphaantitrypsin zaat  info grifols fractionation facility in clayton receives the ispe  facility of the year award the international society for pharmaceutical engineering awarded the prize to the north fractionation facility in the category for project execution  info grifols los angeles site is awarded highly protected risk hpr status the hpr award recognizes the highest level asite can achieve in terms of prevention and protection  info grifols celebrates world hemophilia day with donation of coagulation medicines to the world federation of hemophilia threeyear commitment of up to  million units per year of blood clotting medicines to treat hemophilia patients in developing countries  info grifols opens new plasma fractionation plant in spain the company has invested over  million euros doubling its plasma fractionation capacity in spain  info japanese red cross selects grifols as partner for nucleic acid screening of nations blood supply japanese red cross will use the procleix® panther® platform to screen approximately  million blood donations each year for hiv and hepatitis viruses  info grifols sales rose by  to euros  million in  grifols maintained its position as the third largest producer of plasma derivatives  info grifols opens new head office of araclon biotech in zaragoza spain araclon is an rd company specializing in immunotherapy and diagnosis of alzheimers and other degenerative diseases  info vall dhebron research institute vhri collaborates with grifols to create a center of excellence for research into alpha antitrypsin deficiency the aim of the project is to improve our understanding of patients with alphaantitrypsin deficiency  info the fundació ace with the support of grifols opens a new center for the treatment and research of alzheimers disease the barcelona alzheimer treatment  research center is operated by fundació ace as an independent center with the aim of facilitating the diagnosis and treatment of alzheimers and other neurodegenerative diseases and promoting biomedical research into these conditions  info grifols signs an agreement with cumberland pharmaceuticals to market ibuprofen for intravenous infusion impulses the international growth strategy of the hospital division  info grifols contributes to transfusion medicine education with the third edition of the transfusion science educational course grifols delivers a number of courses each year to help train and advance the careers of transfusion medicine professionals who in turn ensure the quality and safety of the blood transfusions  info grifols announces launch of the spirit registry at the nhf annual meeting grifols inc a leading manufacturer of lifesaving plasmaprotein therapies today announced the launch of the spirit study of plasmaderived factor viiivwf in immune tolerance induction therapy  info grifols introduces the alphakitreg quickscreen a novel pointofcare screening device to detect alphaantitrypsin aat deficiency a leading cause of genetic emphysema  copd in adults details presented at the annual congress of the european respiratory society ers  info grifols announces winners of the th annual ealta research fellowship at  ers congress awards fund early career investigators research to advance understanding and treatment of alphaantitrypsin deficiency  info grifols takes part in the exhibition molecules of life  years of biochemistry and molecular biology in spain grifols sponsors the module dedicated to plasma proteins which consists of an augmented reality system  info grifols implements its first automated inventory management carousel system for investigational pharmacies at emory university the first automated inventory management carousel has been implemented at emory university investigational drug service  info grifols increases its collaboration with the chronic liver failure european consortium the company will contribute three million euros over the next four years in addition to the two million committed since   info award winners at the sixth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways does this is through the martín villar awards for research into haemostasis  info grifols announces transfer of management of melville new york plasma fractionation facility to kedrion today grifols sa grifols announced that effective july   it will transfer management of the melville  info grifols study demonstrates higher dose of prolastinc increases levels of alphapi to within normal range in patients with aat deficiency study results presented at annual meeting of american thoracic society ats  info grifols officially inaugurates new immunoglobulin plant in the united states ivigs are the most important and most widely consumed plasma derived protein therapies  info cadence pharmaceuticals entrust grifols the manufacturing of ofirmev® paracetamol injection in flexible iv bags manufacturing and supply agreement between cadence pharmaceuticals and grifols  info grifols inaugurates the extension to its production facilities in las torres de cotillas murcia the project involved a total investment of  million euros  info grifols announces first patient enrolled and dosed in phase ii trial of alpha hc aerosol to treat cystic fibrosis the multicenter trial will investigate two doses of alpha hc aerosol an inhaled formulation of grifols alphaproteinase inhibitor human  info grifols alzheimer research strategy addresses the degenerative disease from a global perspective the company presented its research projects to coincide with world alzheimers day held on september   info grifols agrees to purchase three plasma donation centers in the united states from canadas cangene once the transaction is concluded grifols has  plasmapheresis centers  info grifols awards winners of the th annual ealta research fellowship at  ers meeting awards fund earlycareer investigators research to advance understanding and treatment of alphaantitrypsin deficiency  info araclon biotech has identified a new blood protein with diagnostic value for alzheimers disease the spanish biotech firm in which grifols has a majority shareholding has presented the first results at the alzheimers association international conference in vancouver canada  info grifols acquires  of the capital of biotechnology firm vcn bioscience the groups investment will ensure the viability of research projects in the field of oncology  info award winners at the fifth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways does this is through the martín villar awards for research into haemostasis  info grifols launches ambar study based on the combined use of plasma derivatives and plasmapheresis to treat alzheimers disease the new ambar study combines therapeutic plasmapheresis with alternating infusion of albumin and intravenous immunoglobulin ivig to treat alzheimers  info grifols is to construct a plant in brazil to manufacture bags for the extraction and conservation of blood components the group has strengthened its manufacturing presence in latin america  info grifols continues to contribute to transfusion medicine training with its second european edition of the transfusion science education course each year grifols holds a number of courses intended to provide an opportunity for transfusion medicine professionals to learn and progress through training we can ensure the quality and safety of the transfusions that millions of people throughout the world receive each year  info grifols extends its commitment to scientific dissemination with a new publication perspectives in transfusion medicine the twiceyearly publication is a means of distributing scientific content developed by leading researchers in the field of transfusion medicine  info grifols opens new state of the art plasma testing laboratory in san marcos the squarefootfacility will create new jobs as well as provide job opportunities for existing grifols employees through consolidation of the companys plasma testing operations at the new san marcos facility and an existing facility in austin texas  info pau gasol introduces new technology donated by grifols to pharmacy at childrens hospital los angeles new equipment designed to enhance safety and efficiency by automating quality control oversight during compounding of medications  info grifols sales increase by  in constant currency terms in  to  millon euros grifols leads global sales of ivig and ap used to treat pulmonary emphysema after talecris acquisition  info award winners at the fourth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways is does this is through the martín villar awards for research into hemostasis  info grifols inaugurates its global headquarters in barcelona  info grifols´ sales grow  to  million euros in the first quarter of  strong growth in the united states where sales increased by  during the quarter higher sales volumes of plasma derivatives such as ivig and factor viii confirm the upward trend in the sector  info grifols establishes expert advisory council in transfusion medicine the role of the expert advisory council is to provide insight advice and guidance to grifols´own transfusion medicine research and development activities  info fda approves revised alphanate® labeling to include reduced infectivity of an experimental model agent for vcjd alphanate® será el primer factor de coagulación sanguínea hemoderivado en incluir en su etiquetado información sobre procesos de fabricación que ofrecen una garantía razonable de eliminación de bajos niveles de un agente considerado modelo de la vecj  info grifols signs cooperative agreement for commercialization of immunohematology diagnostic products in the us agreement will facilitate access to stateoftheart immunohematology products to blood banks and hospitals transfusion centers in the us  info grifols starts construction of a new plasma fractionation plant in parets del vallès the new facilities will deliver up to an additional maximum of two million liters of plasma fractionation capacity in spain raising total capacity from the current figure of  million liters to  million liters  info grifols expands its patientcare program to address insurance lapses in the primary immune deficiency community as part of its ongoing commitment to the primary immune deficiency community grifols offers its ivig therapies at no cost to those who have a lapse in insurance or are in need of temporary assistance  info grifols expands its patientcare program to address insurance lapses in the primary immune deficiency community as part of its ongoing commitment to the primary immune deficiency community grifols offers its ivig therapies at no cost to those who have a lapse in insurance or are in need of temporary assistance  info grifols announces us launch of flebogamma®  dif ivig building on the safety record of its  concentration the new  liquid room temperature ivig preparation establishes grifols as the only producer offering both  and  ivig concentrations to healthcare providers and patients in the us  info grifols announces us launch of flebogamma®  dif ivig building on the safety record of its  concentration the new  liquid room temperature ivig preparation establishes grifols as the only producer offering both  and  ivig concentrations to healthcare providers and patients in the us  info grifols updates the pedigri® website as of today pedigri® has a new website at the following address wwwpedigrigrifolscom  info grifols´ turnover increased by  in the first nine months of  to  mm grifols reaches its highest quarterly turnover exceeding  million euros between july and september  in the third quarter the bioscience division grew by  mainly driven by the us market the higher sale volumes of plasma derivatives such as albumin and ivig with doubledigit increases confirm the upward trend of the sector recurrent ebitda of the business grew by  up to  million euros net profit at  million euros falls by  due to costs associated with the corporate transaction and higher financial expenses  info grifols continues investing to boost its diagnostics division a new plant will produce the mdmulticard® for the rapid determination of blood groups expanding grifols´offer in transfusion diagnostics investment made in production facilities in australia and switzerland amounts to  million euros  info progenika biopharma grants grifols worldwide distribution of its bloodchip® genotyping test for blood donors the spanish biotechnology company progenika biopharma is a pioneer in the development of molecular biology tests for blood transfusion compatibility the bloodchip® global distribution agreement strengthens grifols´the diagnostic division and is expected to generate revenues of between  million over the next  years bloodchip® assures the global reach of the test  info grifols to acquire talecris biotherapeutics creating a world leading provider of lifesaving plasma protein therapies the combination of grifols and talecris will create a diversified global provider of lifesaving and life enhancing plasma protein therapeutics built on the strong global presence of grifols and the established position of talecris in the united states and canada the merger accelerates key strategic initiatives for both talecris and grifols as it creates a more efficient platform for manufacturing innovation and global sales and marketing combining the expertise of both companies will build upon their individual legacies of patient commitment growth and innovation while increasing the availability of high quality plasma protein therapies for patients worldwide  info grifols introduces mixvial™ filter transfer sets a new needlefree transfer set will add to patient convenience and ease of use when reconstituting grifols coagulation therapies  info grifols introduces mixvial™ filter transfer sets a new needlefree transfer set will add to patient convenience and ease of use when reconstituting grifols coagulation therapies  info moving forward in safety grifols introduces a holographic seal on its plasma derivative packaging the holographic seal on its plasma derivative packaging is a an additional measure adopted by grifols in its commitment to giving its products the highest levels of safety  info fundación probitas provides aid for haitian population fundación probitas which was created in  under the auspices of grifols has now started to operate and as its first action has approved emergency aid for the haitian population  info grifols obtains fda approval for new sterile albumin filling plant in los angeles grifols has received approval from the fda for its new sterile albumin filling plant in los angeles this approval is the culmination of a threeyear project to transform the entire process of obtaining purifying and filling albumin vials at grifols biologicals inc los angeles  info grifols publishes interim results of its clinical trial on alzheimers disease the preliminary results of the trial suggest that patients who received treatment showed a trend towards stabilization of the disease the line of investigation was based on the systematic practice of therapeutic plasmapheresis with human albumin grifols in patients with this disease  info work recognised in the nd edition of the martín villar haemostasis awards researcher giancarlo castaman wins first prize for his study into the response of von willebrand patients to treatment with desmopressin  info the annual martin villar haemostasis awards is open to applications el plazo de presentación de candidaturas a los premios martín villar se ha abierto oficialmente con dotaciones económicas que suman un total de  euros para los trabajos ganadores  info grifols promotes european research into liver cirrhosis the european consortium for the study of chronic liver failure created today brings together  centres from across europe and will be coordinated from barcelona´s hospital clínic by professor vicente arroyo  info new method makes it possible to transport medicine cells to areas affected by inflammatory processes this discovery the product of collaboration between research centres and the grifols group of companies is a step towards what has been described as the medicine of the future personalized therapy  info grifols academy of plasmapheresis opens in us based in arizona in the united states the initiative reflects a firm commitment to employee training and knowledge sharing in line with the degree of specialisation required in the plasma derivative industry  info grifols gets a minority stake in cardio biosciences founded by a group of scientists from the cardiovascular center in aalst belgium on a technology developed by researchers at mayo clinic cardio biosciences specialises in stemcell based biotherapeutic rd for the treatment of cardiovascular diseases  info the martin villar haemostasis awards ceremony held in barcelona established by grifols in  these awards pay tribute to the worldrenowned hematologist martín villar and promote research in hemostasis by recognizing the most outstanding basic or clinical research projects on blood coagulation disorders  info grifols presents blispack® an automated blister identification and opening tool for medications in the hospital blispack® was launched at the rd national congress of the hospital pharmacy spanish society in valencia october  to   info grifols acquires office complex in sant cugat the new complex will allow the grifols group to centralize its shared corporate areas while also providing space for future growth these areas are currently based in rented office space primarily in barcelona and without any scope for physical expansion  info grifols breaks ground on new ivig facility the new facility based in los angeles california is anticipated to be operational in  and will expand the companys ability to supply its new generation of intravenous immune globulin into the foreseeable future  info grifols breaks ground on new ivig facility the new facility based in los angeles california is anticipated to be operational in  and will expand the companys ability to supply its new generation of intravenous immune globulin into the foreseeable future  info final stage of implementation of pedigri® on line extends transparency of information to all grifols plasma derivatives grifols has extended pedigri® on line to all of its plasma derivatives including albutein® alphanate® alphanine® and profilnine® sd also as part of the final stage the company has officially launched pedigri® on line in the us market  info grifols obtains fda licence for new filling area at its plasma products plant in the usa the new facilities ensure maximum safety for the sterile filling and lyophilization of grifols coagulation factors the fact that the licence was awarded within  months reflects the company´s experience and reputation in regulatory affairs with the fda  info cardinal health and grifols concluded an exclusive  year distribution agreement cardinal health and grifols concluded an exclusive  year distribution agreement  info grifols signs agreement with stough development corp to open  new plasma collection centers in the united states as a result the spanish group expects to obtain an additional  of its main raw material without allocating any internal resources to this  info       intended for unted states audiences only × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world grifols worldwide  welcome javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world the same commitment and innovation as the first day researching new medical solutions for hospitals delivering health solutions since  choose country europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world corporate news grifols increases its revenues by  to eur  million driven by growth of its main divisions first half of  results  info winner of the  spin award program grifols scientific awards  info grifols opens new lines of research with the acquisition of a  stake in gigagen for usd  million grifols strengthens its rdi through investee companies  info highlights manufacturing we are a solid company with an international dimension choosediagnostic grifolsgrifols engineeringinstituto grifols and grifols biologicalsbiomatgrifols plasma operationslaboratorios grifols corporate commitment we contribute to improving peoples health and wellbeing by offering safe high quality products produced using the latest environmentally friendly technology chooseenvironmentvictor grifols foundationannual report grifols academy  when a dream comes true an illustrated history of  years of grifols read when a dream comes true an illustrated history of  years of grifols to discover the companys roots and learn more about our history and the development of the company   info     the information contained on the grifols worldwide website is not applicable to all countries for specific information on the products available in your country please select your country from the list at the top of the page × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world grifols united states  view news javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand united states   home   products   us corporate responsibility   news and events   contact europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world pioneering spirit united states home products us corporate responsibility news and events contact europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world united states  news and events  view news news and events press center new event category corporativecorporativa investorsinversores productproducto select year                    grifols increases its revenues by  to eur  million driven by growth of its main divisions  jul   first half of  results winner of the  spin award program  jul   grifols scientific awards grifols opens new lines of research with the acquisition of a  stake in gigagen for usd  million  jul   grifols strengthens its rdi through investee companies grifols voluntarily discloses transfers of value  jun   the company adopted the efpia code of conduct in  araclon biotech initiates phase ii clinical trials of its alzheimers vaccine  jun   after receiving approval from the spanish agency of medicinal products and medical devices grifols awards one million dollar grant to support the alpha foundations john w walsh research fund  jun   honoring the memory of john w walsh cofounder of the alpha foundation grifols continues to strengthen its diagnostic division by launching new global testing services for the measurement of biological drug levels and antidrug immune response in blood samples  jun   grifols launches new therapeutic drug monitoring testing services for the biologic drugs infliximab adalimumab and vedolizumab grifols and beckman coulter enter into an exclusive distribution agreement  jun   multiyear agreement advances companies objectives to provide diagnostics solutions that support and improve patient care grifols physiological saline solution produced in its murcia facility receives us fda approval  jun   grifols hospital division gains momentum in the us grifols allocates euros  million to dividends with a compound annual growth rate of  over the last  years  may   grifols holds its ordinary annual general shareholders meeting with more than  of its share capital represented grifols makes procleix zika virus assay available for screening blood donations to countries accepting ce mark  may   grifols strengthens its procleix portfolio with the ce marking for procleix zika virus assay investigational new drug application is now effective for babesia screening in blood donations using grifols procleix panther system in the us  may   fda has allowed the use of the test under an investigational new drug ind study for selected blood banks in the us bioscience division sales increase  to drive grifols revenue growth by  to euros  million  may   first quarter  results grifols strengthens position as global provider of diagnostic testing solutions with fiveyear extension of orasure technologies agreement and a new manufacturing facility  apr   longstanding relationship between companies fortified by multiyear contract extension grifols donates  million international units of blood clotting factors to the world federation of hemophilia humanitarian aid program  apr   helping treat tensofthousands of patients in developing countries renewing partnership with wfh reaffirming commitment to improving the lives of patients around the world the president of the company víctor grífols roura honored with the distinction creu de sant jordi  apr   the creu de sant jordi one of the highest honors awarded by the government of catalonia grifols participates at the rd international conference on research into alpha antitrypsin deficiency and the th international congress of alpha patients  apr   patients and researchers from across the world are meeting to discuss the latest scientific advances in alpha antitrypsin deficiency a rare genetic disease that can cause respiratory illness particularly emphysema grifols revenues exceed euros  million driven by  growth of the bioscience division  feb   annual results  grifols refinances debt for usd  billion reducing the margin to  bps and extending its maturities  feb   the company has concluded its debt refinancing process substantially improving all conditions grifols closes the acquisition of hologics share of nat donor screening unit for usd  million  jan   the company consolidates a leading position of its diagnostic division enhancing its integration         next    intended for unted states audiences only × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world grifols spain  our company javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand spain   home   products   news  events   contact europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world reaching communities around the world spain home products news  events contact europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world spain  home  our company our company supporting investigational research grifols movaco sa grifols spanish distribution subsidiary grifols movaco sa is a grifols sa subsidiary dedicated to the storage commercialization and distribution of products manufactured by the groups various businesses as well as those produced by several thirdparty companies in addition to these services the company also provides aftersales support to purchasers movacos six spanish facilities offer direct accessible service with their specialized sales network and aftersales technical support for all of their products and services the company has been iso  certified since  and was recertified for iso  in  since december  movaco is certified by the new iso  standard the company also holds iso  environmental management certification as well as ohsas  management system certification movaco received its wholesale distribution license in august  as well as its gdp good distribution practice certificate the companys mission and commitment to quality and stakeholder involvement are outlined in its quality policy statement grifols movaco sa c palou   polígono industrial levante  parets del vallès barcelona barcelona spain tel    fax    movacogrifolscom atencionclientesgrifolscom see regional offices web wwwgrifolscom see on map news grifols increases its revenues by  to eur  million driven by growth of its main divisions first half of  results  info winner of the  spin award program grifols scientific awards  info grifols opens new lines of research with the acquisition of a  stake in gigagen for usd  million grifols strengthens its rdi through investee companies  info grifols voluntarily discloses transfers of value the company adopted the efpia code of conduct in   info araclon biotech initiates phase ii clinical trials of its alzheimers vaccine after receiving approval from the spanish agency of medicinal products and medical devices  info grifols awards one million dollar grant to support the alpha foundations john w walsh research fund honoring the memory of john w walsh cofounder of the alpha foundation  info grifols and beckman coulter enter into an exclusive distribution agreement multiyear agreement advances companies objectives to provide diagnostics solutions that support and improve patient care  info grifols physiological saline solution produced in its murcia facility receives us fda approval grifols hospital division gains momentum in the us  info grifols allocates euros  million to dividends with a compound annual growth rate of  over the last  years grifols holds its ordinary annual general shareholders meeting with more than  of its share capital represented  info grifols makes procleix zika virus assay available for screening blood donations to countries accepting ce mark grifols strengthens its procleix portfolio with the ce marking for procleix zika virus assay  info bioscience division sales increase  to drive grifols revenue growth by  to euros  million first quarter  results  info grifols strengthens position as global provider of diagnostic testing solutions with fiveyear extension of orasure technologies agreement and a new manufacturing facility longstanding relationship between companies fortified by multiyear contract extension  info grifols donates  million international units of blood clotting factors to the world federation of hemophilia humanitarian aid program helping treat tensofthousands of patients in developing countries renewing partnership with wfh reaffirming commitment to improving the lives of patients around the world  info the president of the company víctor grífols roura honored with the distinction creu de sant jordi the creu de sant jordi one of the highest honors awarded by the government of catalonia  info grifols participates at the rd international conference on research into alpha antitrypsin deficiency and the th international congress of alpha patients patients and researchers from across the world are meeting to discuss the latest scientific advances in alpha antitrypsin deficiency a rare genetic disease that can cause respiratory illness particularly emphysema  info grifols revenues exceed euros  million driven by  growth of the bioscience division annual results   info grifols refinances debt for usd  billion reducing the margin to  bps and extending its maturities the company has concluded its debt refinancing process substantially improving all conditions  info grifols closes the acquisition of hologics share of nat donor screening unit for usd  million the company consolidates a leading position of its diagnostic division enhancing its integration  info grifols agrees to acquire hologics share of nat donor screening unit for usd  million the company consolidates a leading position of its diagnostic division enhancing its integration  info sales of the bioscience division grow by  increasing grifols revenues to eur  million results for the nine months ended september   info grifols relocates its headquarters in germany to a new office building grifols has a commercial subsidiary in germany since  and following the acquisition of talecris in  the country also hosts the commercial headquarters of the bioscience division in europe  info grifols opens diagnostic training center in dubai the new center part of grifols growing diagnostic business will train laboratory technicians engineers and specialists on grifols systems and laboratory best practices  info grifls supports the canadian blood services missing type campaign grifls is proud to support the canadian blood services missing type campaign this is a global campaign whose goal is to increase the number of new registered blood donors in the last decade there has been a downward trend of new registered blood donors which may put the blood supply at risk  info the results of phase i clinical trial of the araclon biotech alzheimers vaccine support its continuation the conclusions of the trial were presented at the alzheimers association international conference in toronto the compound abvac designed to combat alzheimers disease at its initial stage has demonstrated a good safety and tolerability profile  info sales of the bioscience division grow by  increasing grifols revenues by  to eur  million results for the first half of   info award winners of the th annual martín villar haemostasis awards the awards ceremony was held at the symposium organized by grifols at the wfh world congress in orlando on july    info grifols agrees to acquire a  sq ft plot of land to expand its production facilities in barcelona spain the plot is located in the spanish town of lliçà de vall a future industrial park adjacent to the industrial park of llevant of parets del vallès where currently grifols has production facilities  info pedigri® the tool that increases the information transparency to the plasmaderived manufactured in clayton gammastan® gamunex®  gamunexc® hyperhep b® hyperrab® hyperrho® hypertet® koāte® dvi plasbumin® prolastin®  prolastin® c and thrombate® iii are the newly added products  info award winner of the  spin awards program created in  the spin awards program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology  info fda approves use of the procleix zika virus assay from hologic and grifols to screen the us blood supply under an ind study protocol blood banks will use the new test codeveloped by hologic and grifols to screen donated blood in potential endemic areas of the us  info grifols allocates eur  million to dividends and maintains payout at  of consolidated net profit grifols ordinary general meeting of shareholders  info sippet an international randomized study reports  higher incidence of inhibitors with recombinant factor viii in patients with severe hemophilia a results of the study have just been published in the may th issue of the new england journal of medicine  info grifols revenues increase by  to euros  million driven by growth of  for the bioscience division the company has announced a new industrial expansion plan and continues with its initiatives to increase access to plasma  info the catalan downs syndrome foundation and grifols are working together to promote research grifols has donated  euros to support the foundations research effort designed to improve the quality of life of people with intellectual disability  info lurie childrens hospital selects grifols kiro® robot to increase precision safety and compliance of pediatric iv chemotherapy handling and compounding grifols kiro robotic system provides nextgeneration precision and automation for sterile compounding of iv medications  info the company doesn´t have any tax litigation in any country where it operates because of the dissemination of some information with regard the grifols sa  consolidated annual accounts filed with the cnmv last monday the company would like to clarify the following points  info grifols revenues grow by  to euros  million and net profit grows by  reaching euros  million grifols mce grf mce grfp and nasdaq grfs reported net revenues of euros  million for  growing  compared to euros  million reported in  exchange rates movements in particular of the us dollar had a positive impact on revenues that grew  at constant currency cc  info grifols invests in the project led by albajuna therapeutics a spinoff from irsicaixa to fund the development of therapeutic antibodies against hiv albajuna therapeutics a spinoff from the irsicaixa aids research institute is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize hiv and activate the natural killer cells responsible for destroying cells infected by the virus  info grifols obtains exclusive rights to market and distribute massbiologics tetanus and diphtheria toxoids adsorbed td vaccine in us almost all cases of tetanus in the us occur in people who have never been immunized or who have not had a tetanus booster shot within the preceding  years  info grifols makes public its succession plan the envisaged generational handover reiterates the commitment of the founding family to the company from  january  victor grifols roura will be succeeded by his brother raimon grifols and his son víctor grifols deu who will become joint and several chief executive officers of the company víctor grifols will continue holding his position as nonexecutive chairman of the board of directors  info the sippet study on inhibitors in hemophilia a reports a higher incidence of inhibitors with recombinant factor viii than plasmaderived factor viii containing von willebrand factor the results may have implications in the choice of products for management in previously untreated patients pups with severe hemophilia a  info inauguration of the grifols chair for the study of cirrhosis the grifols chair for the study of cirrhosis a private chair with an international reach was created to promote research and education on liver diseases especially cirrhosis  info the intermediate results from the grifols ambar study support its continuation the intermediate results show the tolerability and safety of the treatment  info grifols agrees long term loan with the european investment bank grifols is one of the first companies to receive funding from the european investment bank eib through the new european fund for strategic investments efsi  info grifols official opening of the bioscience division new worldwide operations facility in ireland total investment in the project reaches  million dollars and is a fundamental part of grifols growth strategy  info grifols announces the  alta award winners during the ers congress in amsterdam the annual alta award sponsored exclusively by grifols provides two fellowships of € to young investigators and clinicians whose work contributes to the understanding and treatment of alphaantitrypsin deficiency aat deficiency  info grifols antithrombin research awards gatra program  on october th the ceremony for the first edition of the gatra program grifols scientific awards about research on antithrombin was held at the museu grifols in barcelona  info albumin awards program albus  berlin held the ceremony of the first edition of the albus awards  info spin award program  the spin award program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology  info award winners at the th annual martín villar haemostasis awards  info dr víctor grífols i lucas – dr víctor grífols i lucas passed away in barcelona on june the st   info grifols to make a major equity investment in alkahest alkahest is a company founded in  by leading scientists who demonstrated at stanford university us that factors in the blood of young animals were able to restore mental capabilities in old animals  info grifols achieves a record net profit of  million euros with growth of  in  grifols net revenues rose by  to  million euros  info grifols phocusrx certified diacap compliant the phocusrx system can operate with a low and acceptable level of risk when installed in a department of defense facility that meets security requirements  info sippet study on inhibitors in hemophilia a interim analysis confirms the original hypothesis the study is safe to continue after investigators meeting and the disclosure of interim analysis in san francisco  info grifols partners with johnston county educators to develop science program discover the plasma program will enhance the eighth grade curriculum in johnston county middle schools and raise awareness about lifesaving plasma therapies  info grifols receives fda approval for its new purification plant to produce gamunex in los angeles the plant located in los angeles california represents an investment of  million euros and over  new jobs will be created when it starts operation in   info grifols contributes to river restoration projects restoring the course of the river tenes and a study of the reintroduction of otters are the focus of a cooperation agreement with the consortium for the protection of the river besós basin  info grifols introduces new g ivig vial size for gamunexc the widest range of vial sizes expands convenience options for ig therapy  info investigating inhibitor development in patients with hemophilia a lecture on stateoftheart of the sippet study presented by pm mannucci sponsored by grifols kedrion and lfb  info grifols presents its gatra scholarship program to promote research on antithrombin therapy the gatra program grifols antithrombin research awards was announced on october  world thrombosis day and grants two yearly scholarships of  euros each for a month period of research  info grifols reinforces its commitment to research in the th edition of the martín villar awards for research on hemostasis created in  the awards recognize progress made in the field of hemostasis the awards are endowed with  euros for each of the two prizes basic research and clinical research  info grifols acquires  of the share capital of kiro robotics for  million euros grifols strengthens its commitment to research and promotes the international growth of its hospital division  info grifols achieves ten years of research into alzheimers in the last decade the company has developed a comprehensive strategy for research into the disease and currently has three clinical trials underway  info new highly sensitive test to screen donors of blood tissues and organs for hepatitis e virus receives ce mark the test which uses nucleic acid technology nat to detect hepatitis e virus will run on the fully automated procleix®panther®system in the eu  info award winners at the seventh edition of the martín villar research awards martín villar research awards   info grifols launches a continuing education program for transfusion medicine professionals in the united states the program is designed to update knowledge and share advances in the field of transfusion safety  info grifols opens stateoftheart facility in clayton nc to help advance treatment of rare and lifethreatening diseases grifols north fractionation facility will be the worlds largest and one of the most technologically advanced plasma fractionation facilities increasing production capacity in clayton from  million liters of plasma annually to  million liters in   info grifols announces availability in europe of alphakit®quickscreen a novel pointofcare screening device to aid in the detection of alphaantitrypsin deficiency aatd alphakit® quickscreen is a novel pointofcare immunochromatographic in vitro diagnostic screening test for the zform of alphaantitrypsin zaat  info grifols fractionation facility in clayton receives the ispe  facility of the year award the international society for pharmaceutical engineering awarded the prize to the north fractionation facility in the category for project execution  info grifols los angeles site is awarded highly protected risk hpr status the hpr award recognizes the highest level asite can achieve in terms of prevention and protection  info grifols celebrates world hemophilia day with donation of coagulation medicines to the world federation of hemophilia threeyear commitment of up to  million units per year of blood clotting medicines to treat hemophilia patients in developing countries  info grifols opens new plasma fractionation plant in spain the company has invested over  million euros doubling its plasma fractionation capacity in spain  info japanese red cross selects grifols as partner for nucleic acid screening of nations blood supply japanese red cross will use the procleix® panther® platform to screen approximately  million blood donations each year for hiv and hepatitis viruses  info grifols sales rose by  to euros  million in  grifols maintained its position as the third largest producer of plasma derivatives  info grifols opens new head office of araclon biotech in zaragoza spain araclon is an rd company specializing in immunotherapy and diagnosis of alzheimers and other degenerative diseases  info vall dhebron research institute vhri collaborates with grifols to create a center of excellence for research into alpha antitrypsin deficiency the aim of the project is to improve our understanding of patients with alphaantitrypsin deficiency  info the fundació ace with the support of grifols opens a new center for the treatment and research of alzheimers disease the barcelona alzheimer treatment  research center is operated by fundació ace as an independent center with the aim of facilitating the diagnosis and treatment of alzheimers and other neurodegenerative diseases and promoting biomedical research into these conditions  info grifols signs an agreement with cumberland pharmaceuticals to market ibuprofen for intravenous infusion impulses the international growth strategy of the hospital division  info grifols contributes to transfusion medicine education with the third edition of the transfusion science educational course grifols delivers a number of courses each year to help train and advance the careers of transfusion medicine professionals who in turn ensure the quality and safety of the blood transfusions  info grifols introduces the alphakitreg quickscreen a novel pointofcare screening device to detect alphaantitrypsin aat deficiency a leading cause of genetic emphysema  copd in adults details presented at the annual congress of the european respiratory society ers  info grifols announces winners of the th annual ealta research fellowship at  ers congress awards fund early career investigators research to advance understanding and treatment of alphaantitrypsin deficiency  info grifols takes part in the exhibition molecules of life  years of biochemistry and molecular biology in spain grifols sponsors the module dedicated to plasma proteins which consists of an augmented reality system  info grifols implements its first automated inventory management carousel system for investigational pharmacies at emory university the first automated inventory management carousel has been implemented at emory university investigational drug service  info grifols increases its collaboration with the chronic liver failure european consortium the company will contribute three million euros over the next four years in addition to the two million committed since   info award winners at the sixth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways does this is through the martín villar awards for research into haemostasis  info grifols announces transfer of management of melville new york plasma fractionation facility to kedrion today grifols sa grifols announced that effective july   it will transfer management of the melville  info grifols study demonstrates higher dose of prolastinc increases levels of alphapi to within normal range in patients with aat deficiency study results presented at annual meeting of american thoracic society ats  info grifols officially inaugurates new immunoglobulin plant in the united states ivigs are the most important and most widely consumed plasma derived protein therapies  info cadence pharmaceuticals entrust grifols the manufacturing of ofirmev® paracetamol injection in flexible iv bags manufacturing and supply agreement between cadence pharmaceuticals and grifols  info grifols inaugurates the extension to its production facilities in las torres de cotillas murcia the project involved a total investment of  million euros  info grifols alzheimer research strategy addresses the degenerative disease from a global perspective the company presented its research projects to coincide with world alzheimers day held on september   info grifols agrees to purchase three plasma donation centers in the united states from canadas cangene once the transaction is concluded grifols has  plasmapheresis centers  info grifols awards winners of the th annual ealta research fellowship at  ers meeting awards fund earlycareer investigators research to advance understanding and treatment of alphaantitrypsin deficiency  info araclon biotech has identified a new blood protein with diagnostic value for alzheimers disease the spanish biotech firm in which grifols has a majority shareholding has presented the first results at the alzheimers association international conference in vancouver canada  info grifols acquires  of the capital of biotechnology firm vcn bioscience the groups investment will ensure the viability of research projects in the field of oncology  info award winners at the fifth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways does this is through the martín villar awards for research into haemostasis  info grifols launches ambar study based on the combined use of plasma derivatives and plasmapheresis to treat alzheimers disease the new ambar study combines therapeutic plasmapheresis with alternating infusion of albumin and intravenous immunoglobulin ivig to treat alzheimers  info grifols is to construct a plant in brazil to manufacture bags for the extraction and conservation of blood components the group has strengthened its manufacturing presence in latin america  info grifols continues to contribute to transfusion medicine training with its second european edition of the transfusion science education course each year grifols holds a number of courses intended to provide an opportunity for transfusion medicine professionals to learn and progress through training we can ensure the quality and safety of the transfusions that millions of people throughout the world receive each year  info grifols extends its commitment to scientific dissemination with a new publication perspectives in transfusion medicine the twiceyearly publication is a means of distributing scientific content developed by leading researchers in the field of transfusion medicine  info grifols opens new state of the art plasma testing laboratory in san marcos the squarefootfacility will create new jobs as well as provide job opportunities for existing grifols employees through consolidation of the companys plasma testing operations at the new san marcos facility and an existing facility in austin texas  info pau gasol introduces new technology donated by grifols to pharmacy at childrens hospital los angeles new equipment designed to enhance safety and efficiency by automating quality control oversight during compounding of medications  info grifols sales increase by  in constant currency terms in  to  millon euros grifols leads global sales of ivig and ap used to treat pulmonary emphysema after talecris acquisition  info award winners at the fourth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways is does this is through the martín villar awards for research into hemostasis  info grifols inaugurates its global headquarters in barcelona  info grifols´ sales grow  to  million euros in the first quarter of  strong growth in the united states where sales increased by  during the quarter higher sales volumes of plasma derivatives such as ivig and factor viii confirm the upward trend in the sector  info grifols establishes expert advisory council in transfusion medicine the role of the expert advisory council is to provide insight advice and guidance to grifols´own transfusion medicine research and development activities  info grifols signs cooperative agreement for commercialization of immunohematology diagnostic products in the us agreement will facilitate access to stateoftheart immunohematology products to blood banks and hospitals transfusion centers in the us  info grifols starts construction of a new plasma fractionation plant in parets del vallès the new facilities will deliver up to an additional maximum of two million liters of plasma fractionation capacity in spain raising total capacity from the current figure of  million liters to  million liters  info grifols obtains ema license to market its flebogamma® dif at  concentration · the approval means that grifols now offers two concentrations of intravenous immunoglobulin ivig  and  allowing it to better respond to the needs of european health professionals and patients · grifols´patented production process developed at its barcelona plant ensures the highest standards of product quality and safety  info grifols updates the pedigri® website as of today pedigri® has a new website at the following address wwwpedigrigrifolscom  info grifols´ turnover increased by  in the first nine months of  to  mm grifols reaches its highest quarterly turnover exceeding  million euros between july and september  in the third quarter the bioscience division grew by  mainly driven by the us market the higher sale volumes of plasma derivatives such as albumin and ivig with doubledigit increases confirm the upward trend of the sector recurrent ebitda of the business grew by  up to  million euros net profit at  million euros falls by  due to costs associated with the corporate transaction and higher financial expenses  info grifols continues investing to boost its diagnostics division a new plant will produce the mdmulticard® for the rapid determination of blood groups expanding grifols´offer in transfusion diagnostics investment made in production facilities in australia and switzerland amounts to  million euros  info grifols to develop fundació clínic device designed to increase the viability of livers for transplant · the device which has been patented by fundació clínic will be manufactured and marketed by grifols it is based on the principle of preserving livers for transplant in conditions which are similar to those inside the body as against the cold storage methods currently used and this should significantly increase the number of viable livers available for transplant · the licensing and cooperation agreement signed between the two companies provides a basis for adapting the device for human use and taking it to clinical trial to validate its use  info progenika biopharma grants grifols worldwide distribution of its bloodchip® genotyping test for blood donors the spanish biotechnology company progenika biopharma is a pioneer in the development of molecular biology tests for blood transfusion compatibility the bloodchip® global distribution agreement strengthens grifols´the diagnostic division and is expected to generate revenues of between  million over the next  years bloodchip® assures the global reach of the test  info grifols to acquire talecris biotherapeutics creating a world leading provider of lifesaving plasma protein therapies the combination of grifols and talecris will create a diversified global provider of lifesaving and life enhancing plasma protein therapeutics built on the strong global presence of grifols and the established position of talecris in the united states and canada the merger accelerates key strategic initiatives for both talecris and grifols as it creates a more efficient platform for manufacturing innovation and global sales and marketing combining the expertise of both companies will build upon their individual legacies of patient commitment growth and innovation while increasing the availability of high quality plasma protein therapies for patients worldwide  info moving forward in safety grifols introduces a holographic seal on its plasma derivative packaging the holographic seal on its plasma derivative packaging is a an additional measure adopted by grifols in its commitment to giving its products the highest levels of safety  info fundación probitas provides aid for haitian population fundación probitas which was created in  under the auspices of grifols has now started to operate and as its first action has approved emergency aid for the haitian population  info grifols obtains fda approval for new sterile albumin filling plant in los angeles grifols has received approval from the fda for its new sterile albumin filling plant in los angeles this approval is the culmination of a threeyear project to transform the entire process of obtaining purifying and filling albumin vials at grifols biologicals inc los angeles  info grifols publishes interim results of its clinical trial on alzheimers disease the preliminary results of the trial suggest that patients who received treatment showed a trend towards stabilization of the disease the line of investigation was based on the systematic practice of therapeutic plasmapheresis with human albumin grifols in patients with this disease  info grifols launches niuliva® grifols has launched of niuliva®  iuml its human antihepatitis b immunoglobulin for intravenous administration in spain and italy the manufacturing process of niuliva® produces a high purity pasteurized solution with a high titer of specific antihepatitis b antibodies  info work recognised in the nd edition of the martín villar haemostasis awards researcher giancarlo castaman wins first prize for his study into the response of von willebrand patients to treatment with desmopressin  info the annual martin villar haemostasis awards is open to applications el plazo de presentación de candidaturas a los premios martín villar se ha abierto oficialmente con dotaciones económicas que suman un total de  euros para los trabajos ganadores  info grifols promotes european research into liver cirrhosis the european consortium for the study of chronic liver failure created today brings together  centres from across europe and will be coordinated from barcelona´s hospital clínic by professor vicente arroyo  info new method makes it possible to transport medicine cells to areas affected by inflammatory processes this discovery the product of collaboration between research centres and the grifols group of companies is a step towards what has been described as the medicine of the future personalized therapy  info grifols academy of plasmapheresis opens in us based in arizona in the united states the initiative reflects a firm commitment to employee training and knowledge sharing in line with the degree of specialisation required in the plasma derivative industry  info grifols gets a minority stake in cardio biosciences founded by a group of scientists from the cardiovascular center in aalst belgium on a technology developed by researchers at mayo clinic cardio biosciences specialises in stemcell based biotherapeutic rd for the treatment of cardiovascular diseases  info the martin villar haemostasis awards ceremony held in barcelona established by grifols in  these awards pay tribute to the worldrenowned hematologist martín villar and promote research in hemostasis by recognizing the most outstanding basic or clinical research projects on blood coagulation disorders  info grifols presents blispack® an automated blister identification and opening tool for medications in the hospital blispack® was launched at the rd national congress of the hospital pharmacy spanish society in valencia october  to   info grifols acquires office complex in sant cugat the new complex will allow the grifols group to centralize its shared corporate areas while also providing space for future growth these areas are currently based in rented office space primarily in barcelona and without any scope for physical expansion  info final stage of implementation of pedigri® on line extends transparency of information to all grifols plasma derivatives grifols has extended pedigri® on line to all of its plasma derivatives including albutein® alphanate® alphanine® and profilnine® sd also as part of the final stage the company has officially launched pedigri® on line in the us market  info grifols signs an agreement with gambro renal products grp for mars® in spain and portugal grifols in line with its commitment to offer the most advanced products and services to health professionals has signed a distribution agreement for mars® liver support therapy for spain and portugal  info grifols will act as the logistics operator of denia hospital after reaching an agreement with marina salud the outsourcing of hospital logistics is a new development in the spanish health sector the agreement will be valid for a period of  years with an option to extend for a further  years for an estimated value of over  million euros  info cardinal health and grifols concluded an exclusive  year distribution agreement cardinal health and grifols concluded an exclusive  year distribution agreement  info grifols signs a new distribution agreement with cdex grifols signs a new distribution agreement with cdex for spain portugal and italy  info grifols signs agreement with stough development corp to open  new plasma collection centers in the united states as a result the spanish group expects to obtain an additional  of its main raw material without allocating any internal resources to this  info        intended for spain audiences only × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world grifols united states  home javascript is disabled please turn on it we use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits if you continue browsing the website you accept its installation and use as aforementioned you may modify the settings and obtain more information here english spanish contact · sitemap · rss contact sitemap rss search choose product by country from specialist to specialist grifols has created three division that offer specialized products and services grouped according to the distinctive populations they serve europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand united states   home   products   us corporate responsibility   news and events   contact europe middle east and africa   czech republic   dubai   france   germany   italy   nordic countries   poland   portugal   slovakia   spain   switzerland   united kingdom north america   canada   mexico   united states south america   argentina   brazil   chile   colombia asia pacific   australia   japan southeast asia   china   malaysia   singapore   thailand geographical areas   asiapacific   latin america   rest of the world pioneering spirit united states home products us corporate responsibility news and events contact europe middle east and africa  czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america  canada mexico united states south america  argentina brazil chile colombia asia pacific  australia japan southeast asia  china malaysia singapore thailand geographical areas  asiapacific latin america rest of the world united states  home our company our products our leadership our patients our donors grifols usa from our family to your family a heritage of caring grifols is a global healthcare company whose mission is to improve the health and well being of people around the world we accomplish this mission by producing lifesaving protein therapies for patients and by providing hospitals pharmacies and healthcare professionals with the products they need to deliver expert medical care grifols has been working in the fields of transfusion blood banking protein therapeutics and laboratory analysis for more than  years founded in  by dr ja grifols roig three generations of the grifols family have led the company ever since today our grifols sa president victor grifols ensures that the company remains focused on what matters most people our dedication to the advancement of healthcare for humankind is evidenced by our strong global presence we distribute products in  countries plasma safety   news grifols increases its revenues by  to eur  million driven by growth of its main divisions first half of  results  info winner of the  spin award program grifols scientific awards  info grifols opens new lines of research with the acquisition of a  stake in gigagen for usd  million grifols strengthens its rdi through investee companies  info grifols voluntarily discloses transfers of value the company adopted the efpia code of conduct in   info araclon biotech initiates phase ii clinical trials of its alzheimers vaccine after receiving approval from the spanish agency of medicinal products and medical devices  info grifols awards one million dollar grant to support the alpha foundations john w walsh research fund honoring the memory of john w walsh cofounder of the alpha foundation  info grifols continues to strengthen its diagnostic division by launching new global testing services for the measurement of biological drug levels and antidrug immune response in blood samples grifols launches new therapeutic drug monitoring testing services for the biologic drugs infliximab adalimumab and vedolizumab  info grifols and beckman coulter enter into an exclusive distribution agreement multiyear agreement advances companies objectives to provide diagnostics solutions that support and improve patient care  info grifols physiological saline solution produced in its murcia facility receives us fda approval grifols hospital division gains momentum in the us  info grifols allocates euros  million to dividends with a compound annual growth rate of  over the last  years grifols holds its ordinary annual general shareholders meeting with more than  of its share capital represented  info grifols makes procleix zika virus assay available for screening blood donations to countries accepting ce mark grifols strengthens its procleix portfolio with the ce marking for procleix zika virus assay  info investigational new drug application is now effective for babesia screening in blood donations using grifols procleix panther system in the us fda has allowed the use of the test under an investigational new drug ind study for selected blood banks in the us  info bioscience division sales increase  to drive grifols revenue growth by  to euros  million first quarter  results  info grifols strengthens position as global provider of diagnostic testing solutions with fiveyear extension of orasure technologies agreement and a new manufacturing facility longstanding relationship between companies fortified by multiyear contract extension  info grifols donates  million international units of blood clotting factors to the world federation of hemophilia humanitarian aid program helping treat tensofthousands of patients in developing countries renewing partnership with wfh reaffirming commitment to improving the lives of patients around the world  info the president of the company víctor grífols roura honored with the distinction creu de sant jordi the creu de sant jordi one of the highest honors awarded by the government of catalonia  info grifols participates at the rd international conference on research into alpha antitrypsin deficiency and the th international congress of alpha patients patients and researchers from across the world are meeting to discuss the latest scientific advances in alpha antitrypsin deficiency a rare genetic disease that can cause respiratory illness particularly emphysema  info grifols revenues exceed euros  million driven by  growth of the bioscience division annual results   info grifols refinances debt for usd  billion reducing the margin to  bps and extending its maturities the company has concluded its debt refinancing process substantially improving all conditions  info grifols closes the acquisition of hologics share of nat donor screening unit for usd  million the company consolidates a leading position of its diagnostic division enhancing its integration  info grifols agrees to acquire hologics share of nat donor screening unit for usd  million the company consolidates a leading position of its diagnostic division enhancing its integration  info sales of the bioscience division grow by  increasing grifols revenues to eur  million results for the nine months ended september   info grifols relocates its headquarters in germany to a new office building grifols has a commercial subsidiary in germany since  and following the acquisition of talecris in  the country also hosts the commercial headquarters of the bioscience division in europe  info grifols opens diagnostic training center in dubai the new center part of grifols growing diagnostic business will train laboratory technicians engineers and specialists on grifols systems and laboratory best practices  info grifls supports the canadian blood services missing type campaign grifls is proud to support the canadian blood services missing type campaign this is a global campaign whose goal is to increase the number of new registered blood donors in the last decade there has been a downward trend of new registered blood donors which may put the blood supply at risk  info the results of phase i clinical trial of the araclon biotech alzheimers vaccine support its continuation the conclusions of the trial were presented at the alzheimers association international conference in toronto the compound abvac designed to combat alzheimers disease at its initial stage has demonstrated a good safety and tolerability profile  info sales of the bioscience division grow by  increasing grifols revenues by  to eur  million results for the first half of   info award winners of the th annual martín villar haemostasis awards the awards ceremony was held at the symposium organized by grifols at the wfh world congress in orlando on july    info grifols agrees to acquire a  sq ft plot of land to expand its production facilities in barcelona spain the plot is located in the spanish town of lliçà de vall a future industrial park adjacent to the industrial park of llevant of parets del vallès where currently grifols has production facilities  info pedigri® the tool that increases the information transparency to the plasmaderived manufactured in clayton gammastan® gamunex®  gamunexc® hyperhep b® hyperrab® hyperrho® hypertet® koāte® dvi plasbumin® prolastin®  prolastin® c and thrombate® iii are the newly added products  info award winner of the  spin awards program created in  the spin awards program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology  info fda approves use of the procleix zika virus assay from hologic and grifols to screen the us blood supply under an ind study protocol blood banks will use the new test codeveloped by hologic and grifols to screen donated blood in potential endemic areas of the us  info grifols allocates eur  million to dividends and maintains payout at  of consolidated net profit grifols ordinary general meeting of shareholders  info sippet an international randomized study reports  higher incidence of inhibitors with recombinant factor viii in patients with severe hemophilia a results of the study have just been published in the may th issue of the new england journal of medicine  info grifols revenues increase by  to euros  million driven by growth of  for the bioscience division the company has announced a new industrial expansion plan and continues with its initiatives to increase access to plasma  info the catalan downs syndrome foundation and grifols are working together to promote research grifols has donated  euros to support the foundations research effort designed to improve the quality of life of people with intellectual disability  info lurie childrens hospital selects grifols kiro® robot to increase precision safety and compliance of pediatric iv chemotherapy handling and compounding grifols kiro robotic system provides nextgeneration precision and automation for sterile compounding of iv medications  info the company doesn´t have any tax litigation in any country where it operates because of the dissemination of some information with regard the grifols sa  consolidated annual accounts filed with the cnmv last monday the company would like to clarify the following points  info grifols revenues grow by  to euros  million and net profit grows by  reaching euros  million grifols mce grf mce grfp and nasdaq grfs reported net revenues of euros  million for  growing  compared to euros  million reported in  exchange rates movements in particular of the us dollar had a positive impact on revenues that grew  at constant currency cc  info grifols invests in the project led by albajuna therapeutics a spinoff from irsicaixa to fund the development of therapeutic antibodies against hiv albajuna therapeutics a spinoff from the irsicaixa aids research institute is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize hiv and activate the natural killer cells responsible for destroying cells infected by the virus  info grifols obtains exclusive rights to market and distribute massbiologics tetanus and diphtheria toxoids adsorbed td vaccine in us almost all cases of tetanus in the us occur in people who have never been immunized or who have not had a tetanus booster shot within the preceding  years  info grifols makes public its succession plan the envisaged generational handover reiterates the commitment of the founding family to the company from  january  victor grifols roura will be succeeded by his brother raimon grifols and his son víctor grifols deu who will become joint and several chief executive officers of the company víctor grifols will continue holding his position as nonexecutive chairman of the board of directors  info the sippet study on inhibitors in hemophilia a reports a higher incidence of inhibitors with recombinant factor viii than plasmaderived factor viii containing von willebrand factor the results may have implications in the choice of products for management in previously untreated patients pups with severe hemophilia a  info inauguration of the grifols chair for the study of cirrhosis the grifols chair for the study of cirrhosis a private chair with an international reach was created to promote research and education on liver diseases especially cirrhosis  info the intermediate results from the grifols ambar study support its continuation the intermediate results show the tolerability and safety of the treatment  info grifols agrees long term loan with the european investment bank grifols is one of the first companies to receive funding from the european investment bank eib through the new european fund for strategic investments efsi  info grifols official opening of the bioscience division new worldwide operations facility in ireland total investment in the project reaches  million dollars and is a fundamental part of grifols growth strategy  info grifols announces the  alta award winners during the ers congress in amsterdam the annual alta award sponsored exclusively by grifols provides two fellowships of € to young investigators and clinicians whose work contributes to the understanding and treatment of alphaantitrypsin deficiency aat deficiency  info grifols antithrombin research awards gatra program  on october th the ceremony for the first edition of the gatra program grifols scientific awards about research on antithrombin was held at the museu grifols in barcelona  info albumin awards program albus  berlin held the ceremony of the first edition of the albus awards  info spin award program  the spin award program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology  info award winners at the th annual martín villar haemostasis awards  info dr víctor grífols i lucas – dr víctor grífols i lucas passed away in barcelona on june the st   info grifols a healthcare company participates in white house upskill summit grifols a global leader in the production of plasmaderived medicines participated in the white house summit on employee upskilling  info alphanate® antihemophilic factorvon willebrand factor human is the preferred pdfviii product for the treatment of hemophilia a among hematologists practicing in an htc alphanate is physician preferred  info grifols to make a major equity investment in alkahest alkahest is a company founded in  by leading scientists who demonstrated at stanford university us that factors in the blood of young animals were able to restore mental capabilities in old animals  info grifols achieves a record net profit of  million euros with growth of  in  grifols net revenues rose by  to  million euros  info grifols phocusrx certified diacap compliant the phocusrx system can operate with a low and acceptable level of risk when installed in a department of defense facility that meets security requirements  info sippet study on inhibitors in hemophilia a interim analysis confirms the original hypothesis the study is safe to continue after investigators meeting and the disclosure of interim analysis in san francisco  info grifols partners with johnston county educators to develop science program discover the plasma program will enhance the eighth grade curriculum in johnston county middle schools and raise awareness about lifesaving plasma therapies  info grifols academy of plasmapheresis awarded accet accreditation grifols a global leader in the production of plasmaderived medicines is pleased to announce that its academy of plasmapheresis has been awarded accreditation by the accrediting council for continuing education and training accet  info grifols receives fda approval for its new purification plant to produce gamunex in los angeles the plant located in los angeles california represents an investment of  million euros and over  new jobs will be created when it starts operation in   info grifols contributes to river restoration projects restoring the course of the river tenes and a study of the reintroduction of otters are the focus of a cooperation agreement with the consortium for the protection of the river besós basin  info grifols introduces new g ivig vial size for gamunexc the widest range of vial sizes expands convenience options for ig therapy  info investigating inhibitor development in patients with hemophilia a lecture on stateoftheart of the sippet study presented by pm mannucci sponsored by grifols kedrion and lfb  info grifols presents its gatra scholarship program to promote research on antithrombin therapy the gatra program grifols antithrombin research awards was announced on october  world thrombosis day and grants two yearly scholarships of  euros each for a month period of research  info grifols reinforces its commitment to research in the th edition of the martín villar awards for research on hemostasis created in  the awards recognize progress made in the field of hemostasis the awards are endowed with  euros for each of the two prizes basic research and clinical research  info grifols acquires  of the share capital of kiro robotics for  million euros grifols strengthens its commitment to research and promotes the international growth of its hospital division  info grifols achieves ten years of research into alzheimers in the last decade the company has developed a comprehensive strategy for research into the disease and currently has three clinical trials underway  info new highly sensitive test to screen donors of blood tissues and organs for hepatitis e virus receives ce mark the test which uses nucleic acid technology nat to detect hepatitis e virus will run on the fully automated procleix®panther®system in the eu  info award winners at the seventh edition of the martín villar research awards martín villar research awards   info grifols launches a continuing education program for transfusion medicine professionals in the united states the program is designed to update knowledge and share advances in the field of transfusion safety  info grifols opens stateoftheart facility in clayton nc to help advance treatment of rare and lifethreatening diseases grifols north fractionation facility will be the worlds largest and one of the most technologically advanced plasma fractionation facilities increasing production capacity in clayton from  million liters of plasma annually to  million liters in   info grifols announces availability in europe of alphakit®quickscreen a novel pointofcare screening device to aid in the detection of alphaantitrypsin deficiency aatd alphakit® quickscreen is a novel pointofcare immunochromatographic in vitro diagnostic screening test for the zform of alphaantitrypsin zaat  info grifols fractionation facility in clayton receives the ispe  facility of the year award the international society for pharmaceutical engineering awarded the prize to the north fractionation facility in the category for project execution  info grifols los angeles site is awarded highly protected risk hpr status the hpr award recognizes the highest level asite can achieve in terms of prevention and protection  info grifols celebrates world hemophilia day with donation of coagulation medicines to the world federation of hemophilia threeyear commitment of up to  million units per year of blood clotting medicines to treat hemophilia patients in developing countries  info grifols opens new plasma fractionation plant in spain the company has invested over  million euros doubling its plasma fractionation capacity in spain  info japanese red cross selects grifols as partner for nucleic acid screening of nations blood supply japanese red cross will use the procleix® panther® platform to screen approximately  million blood donations each year for hiv and hepatitis viruses  info grifols sales rose by  to euros  million in  grifols maintained its position as the third largest producer of plasma derivatives  info grifols opens new head office of araclon biotech in zaragoza spain araclon is an rd company specializing in immunotherapy and diagnosis of alzheimers and other degenerative diseases  info vall dhebron research institute vhri collaborates with grifols to create a center of excellence for research into alpha antitrypsin deficiency the aim of the project is to improve our understanding of patients with alphaantitrypsin deficiency  info the fundació ace with the support of grifols opens a new center for the treatment and research of alzheimers disease the barcelona alzheimer treatment  research center is operated by fundació ace as an independent center with the aim of facilitating the diagnosis and treatment of alzheimers and other neurodegenerative diseases and promoting biomedical research into these conditions  info grifols signs an agreement with cumberland pharmaceuticals to market ibuprofen for intravenous infusion impulses the international growth strategy of the hospital division  info grifols contributes to transfusion medicine education with the third edition of the transfusion science educational course grifols delivers a number of courses each year to help train and advance the careers of transfusion medicine professionals who in turn ensure the quality and safety of the blood transfusions  info grifols announces launch of the spirit registry at the nhf annual meeting grifols inc a leading manufacturer of lifesaving plasmaprotein therapies today announced the launch of the spirit study of plasmaderived factor viiivwf in immune tolerance induction therapy  info grifols introduces the alphakitreg quickscreen a novel pointofcare screening device to detect alphaantitrypsin aat deficiency a leading cause of genetic emphysema  copd in adults details presented at the annual congress of the european respiratory society ers  info grifols announces winners of the th annual ealta research fellowship at  ers congress awards fund early career investigators research to advance understanding and treatment of alphaantitrypsin deficiency  info grifols takes part in the exhibition molecules of life  years of biochemistry and molecular biology in spain grifols sponsors the module dedicated to plasma proteins which consists of an augmented reality system  info grifols implements its first automated inventory management carousel system for investigational pharmacies at emory university the first automated inventory management carousel has been implemented at emory university investigational drug service  info grifols increases its collaboration with the chronic liver failure european consortium the company will contribute three million euros over the next four years in addition to the two million committed since   info award winners at the sixth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways does this is through the martín villar awards for research into haemostasis  info grifols announces transfer of management of melville new york plasma fractionation facility to kedrion today grifols sa grifols announced that effective july   it will transfer management of the melville  info grifols study demonstrates higher dose of prolastinc increases levels of alphapi to within normal range in patients with aat deficiency study results presented at annual meeting of american thoracic society ats  info grifols officially inaugurates new immunoglobulin plant in the united states ivigs are the most important and most widely consumed plasma derived protein therapies  info cadence pharmaceuticals entrust grifols the manufacturing of ofirmev® paracetamol injection in flexible iv bags manufacturing and supply agreement between cadence pharmaceuticals and grifols  info grifols inaugurates the extension to its production facilities in las torres de cotillas murcia the project involved a total investment of  million euros  info grifols announces first patient enrolled and dosed in phase ii trial of alpha hc aerosol to treat cystic fibrosis the multicenter trial will investigate two doses of alpha hc aerosol an inhaled formulation of grifols alphaproteinase inhibitor human  info grifols alzheimer research strategy addresses the degenerative disease from a global perspective the company presented its research projects to coincide with world alzheimers day held on september   info grifols agrees to purchase three plasma donation centers in the united states from canadas cangene once the transaction is concluded grifols has  plasmapheresis centers  info grifols awards winners of the th annual ealta research fellowship at  ers meeting awards fund earlycareer investigators research to advance understanding and treatment of alphaantitrypsin deficiency  info araclon biotech has identified a new blood protein with diagnostic value for alzheimers disease the spanish biotech firm in which grifols has a majority shareholding has presented the first results at the alzheimers association international conference in vancouver canada  info grifols acquires  of the capital of biotechnology firm vcn bioscience the groups investment will ensure the viability of research projects in the field of oncology  info award winners at the fifth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways does this is through the martín villar awards for research into haemostasis  info grifols launches ambar study based on the combined use of plasma derivatives and plasmapheresis to treat alzheimers disease the new ambar study combines therapeutic plasmapheresis with alternating infusion of albumin and intravenous immunoglobulin ivig to treat alzheimers  info grifols is to construct a plant in brazil to manufacture bags for the extraction and conservation of blood components the group has strengthened its manufacturing presence in latin america  info grifols continues to contribute to transfusion medicine training with its second european edition of the transfusion science education course each year grifols holds a number of courses intended to provide an opportunity for transfusion medicine professionals to learn and progress through training we can ensure the quality and safety of the transfusions that millions of people throughout the world receive each year  info grifols extends its commitment to scientific dissemination with a new publication perspectives in transfusion medicine the twiceyearly publication is a means of distributing scientific content developed by leading researchers in the field of transfusion medicine  info grifols opens new state of the art plasma testing laboratory in san marcos the squarefootfacility will create new jobs as well as provide job opportunities for existing grifols employees through consolidation of the companys plasma testing operations at the new san marcos facility and an existing facility in austin texas  info pau gasol introduces new technology donated by grifols to pharmacy at childrens hospital los angeles new equipment designed to enhance safety and efficiency by automating quality control oversight during compounding of medications  info grifols sales increase by  in constant currency terms in  to  millon euros grifols leads global sales of ivig and ap used to treat pulmonary emphysema after talecris acquisition  info award winners at the fourth edition of the martín villar research awards grifols is a company which is committed to encouraging scientific investigation one of the ways is does this is through the martín villar awards for research into hemostasis  info grifols inaugurates its global headquarters in barcelona  info grifols´ sales grow  to  million euros in the first quarter of  strong growth in the united states where sales increased by  during the quarter higher sales volumes of plasma derivatives such as ivig and factor viii confirm the upward trend in the sector  info grifols establishes expert advisory council in transfusion medicine the role of the expert advisory council is to provide insight advice and guidance to grifols´own transfusion medicine research and development activities  info fda approves revised alphanate® labeling to include reduced infectivity of an experimental model agent for vcjd alphanate® será el primer factor de coagulación sanguínea hemoderivado en incluir en su etiquetado información sobre procesos de fabricación que ofrecen una garantía razonable de eliminación de bajos niveles de un agente considerado modelo de la vecj  info grifols signs cooperative agreement for commercialization of immunohematology diagnostic products in the us agreement will facilitate access to stateoftheart immunohematology products to blood banks and hospitals transfusion centers in the us  info grifols starts construction of a new plasma fractionation plant in parets del vallès the new facilities will deliver up to an additional maximum of two million liters of plasma fractionation capacity in spain raising total capacity from the current figure of  million liters to  million liters  info grifols expands its patientcare program to address insurance lapses in the primary immune deficiency community as part of its ongoing commitment to the primary immune deficiency community grifols offers its ivig therapies at no cost to those who have a lapse in insurance or are in need of temporary assistance  info grifols expands its patientcare program to address insurance lapses in the primary immune deficiency community as part of its ongoing commitment to the primary immune deficiency community grifols offers its ivig therapies at no cost to those who have a lapse in insurance or are in need of temporary assistance  info grifols announces us launch of flebogamma®  dif ivig building on the safety record of its  concentration the new  liquid room temperature ivig preparation establishes grifols as the only producer offering both  and  ivig concentrations to healthcare providers and patients in the us  info grifols announces us launch of flebogamma®  dif ivig building on the safety record of its  concentration the new  liquid room temperature ivig preparation establishes grifols as the only producer offering both  and  ivig concentrations to healthcare providers and patients in the us  info grifols updates the pedigri® website as of today pedigri® has a new website at the following address wwwpedigrigrifolscom  info grifols´ turnover increased by  in the first nine months of  to  mm grifols reaches its highest quarterly turnover exceeding  million euros between july and september  in the third quarter the bioscience division grew by  mainly driven by the us market the higher sale volumes of plasma derivatives such as albumin and ivig with doubledigit increases confirm the upward trend of the sector recurrent ebitda of the business grew by  up to  million euros net profit at  million euros falls by  due to costs associated with the corporate transaction and higher financial expenses  info grifols continues investing to boost its diagnostics division a new plant will produce the mdmulticard® for the rapid determination of blood groups expanding grifols´offer in transfusion diagnostics investment made in production facilities in australia and switzerland amounts to  million euros  info progenika biopharma grants grifols worldwide distribution of its bloodchip® genotyping test for blood donors the spanish biotechnology company progenika biopharma is a pioneer in the development of molecular biology tests for blood transfusion compatibility the bloodchip® global distribution agreement strengthens grifols´the diagnostic division and is expected to generate revenues of between  million over the next  years bloodchip® assures the global reach of the test  info grifols to acquire talecris biotherapeutics creating a world leading provider of lifesaving plasma protein therapies the combination of grifols and talecris will create a diversified global provider of lifesaving and life enhancing plasma protein therapeutics built on the strong global presence of grifols and the established position of talecris in the united states and canada the merger accelerates key strategic initiatives for both talecris and grifols as it creates a more efficient platform for manufacturing innovation and global sales and marketing combining the expertise of both companies will build upon their individual legacies of patient commitment growth and innovation while increasing the availability of high quality plasma protein therapies for patients worldwide  info grifols introduces mixvial™ filter transfer sets a new needlefree transfer set will add to patient convenience and ease of use when reconstituting grifols coagulation therapies  info grifols introduces mixvial™ filter transfer sets a new needlefree transfer set will add to patient convenience and ease of use when reconstituting grifols coagulation therapies  info moving forward in safety grifols introduces a holographic seal on its plasma derivative packaging the holographic seal on its plasma derivative packaging is a an additional measure adopted by grifols in its commitment to giving its products the highest levels of safety  info fundación probitas provides aid for haitian population fundación probitas which was created in  under the auspices of grifols has now started to operate and as its first action has approved emergency aid for the haitian population  info grifols obtains fda approval for new sterile albumin filling plant in los angeles grifols has received approval from the fda for its new sterile albumin filling plant in los angeles this approval is the culmination of a threeyear project to transform the entire process of obtaining purifying and filling albumin vials at grifols biologicals inc los angeles  info grifols publishes interim results of its clinical trial on alzheimers disease the preliminary results of the trial suggest that patients who received treatment showed a trend towards stabilization of the disease the line of investigation was based on the systematic practice of therapeutic plasmapheresis with human albumin grifols in patients with this disease  info work recognised in the nd edition of the martín villar haemostasis awards researcher giancarlo castaman wins first prize for his study into the response of von willebrand patients to treatment with desmopressin  info the annual martin villar haemostasis awards is open to applications el plazo de presentación de candidaturas a los premios martín villar se ha abierto oficialmente con dotaciones económicas que suman un total de  euros para los trabajos ganadores  info grifols promotes european research into liver cirrhosis the european consortium for the study of chronic liver failure created today brings together  centres from across europe and will be coordinated from barcelona´s hospital clínic by professor vicente arroyo  info new method makes it possible to transport medicine cells to areas affected by inflammatory processes this discovery the product of collaboration between research centres and the grifols group of companies is a step towards what has been described as the medicine of the future personalized therapy  info grifols academy of plasmapheresis opens in us based in arizona in the united states the initiative reflects a firm commitment to employee training and knowledge sharing in line with the degree of specialisation required in the plasma derivative industry  info grifols gets a minority stake in cardio biosciences founded by a group of scientists from the cardiovascular center in aalst belgium on a technology developed by researchers at mayo clinic cardio biosciences specialises in stemcell based biotherapeutic rd for the treatment of cardiovascular diseases  info the martin villar haemostasis awards ceremony held in barcelona established by grifols in  these awards pay tribute to the worldrenowned hematologist martín villar and promote research in hemostasis by recognizing the most outstanding basic or clinical research projects on blood coagulation disorders  info grifols presents blispack® an automated blister identification and opening tool for medications in the hospital blispack® was launched at the rd national congress of the hospital pharmacy spanish society in valencia october  to   info grifols acquires office complex in sant cugat the new complex will allow the grifols group to centralize its shared corporate areas while also providing space for future growth these areas are currently based in rented office space primarily in barcelona and without any scope for physical expansion  info grifols breaks ground on new ivig facility the new facility based in los angeles california is anticipated to be operational in  and will expand the companys ability to supply its new generation of intravenous immune globulin into the foreseeable future  info grifols breaks ground on new ivig facility the new facility based in los angeles california is anticipated to be operational in  and will expand the companys ability to supply its new generation of intravenous immune globulin into the foreseeable future  info final stage of implementation of pedigri® on line extends transparency of information to all grifols plasma derivatives grifols has extended pedigri® on line to all of its plasma derivatives including albutein® alphanate® alphanine® and profilnine® sd also as part of the final stage the company has officially launched pedigri® on line in the us market  info grifols obtains fda licence for new filling area at its plasma products plant in the usa the new facilities ensure maximum safety for the sterile filling and lyophilization of grifols coagulation factors the fact that the licence was awarded within  months reflects the company´s experience and reputation in regulatory affairs with the fda  info cardinal health and grifols concluded an exclusive  year distribution agreement cardinal health and grifols concluded an exclusive  year distribution agreement  info grifols signs agreement with stough development corp to open  new plasma collection centers in the united states as a result the spanish group expects to obtain an additional  of its main raw material without allocating any internal resources to this  info       intended for unted states audiences only × europe middle east and africa czech republic dubai france germany italy nordic countries poland portugal slovakia spain switzerland united kingdom north america canada mexico united states south america argentina brazil chile colombia asia pacific australia japan southeast asia china malaysia singapore thailand geographical areas asiapacific latin america rest of the world